BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192. [PMID: 11266382 DOI: 10.1053/gast.2001.23256] [Cited by in Crossref: 1338] [Cited by in F6Publishing: 1249] [Article Influence: 63.7] [Reference Citation Analysis]
Number Citing Articles
1 Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T;  LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-110. [PMID: 18503774 DOI: 10.1053/j.gastro.2008.03.078] [Cited by in Crossref: 421] [Cited by in F6Publishing: 382] [Article Influence: 30.1] [Reference Citation Analysis]
2 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
3 Berk PD. Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 2008;48:1362-76. [PMID: 18972439 DOI: 10.1002/hep.22632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
4 Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology. 2009;49:87-96. [PMID: 19053047 DOI: 10.1002/hep.22578] [Cited by in Crossref: 159] [Cited by in F6Publishing: 158] [Article Influence: 12.2] [Reference Citation Analysis]
5 Gan LT, Van Rooyen DM, Koina ME, McCuskey RS, Teoh NC, Farrell GC. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol. 2014;61:1376-1384. [PMID: 25064435 DOI: 10.1016/j.jhep.2014.07.024] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 11.6] [Reference Citation Analysis]
6 Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6. [DOI: 10.1002/hep.1840400411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
7 Motamed N, Miresmail SJ, Rabiee B, Keyvani H, Farahani B, Maadi M, Zamani F. Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease: A population based study. J Diabetes Complications 2016;30:269-74. [PMID: 26718936 DOI: 10.1016/j.jdiacomp.2015.11.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
8 DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, Blumenthal RS, Budoff MJ. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013;227:429-436. [PMID: 23419204 DOI: 10.1016/j.atherosclerosis.2013.01.022] [Cited by in Crossref: 98] [Cited by in F6Publishing: 97] [Article Influence: 10.9] [Reference Citation Analysis]
9 Licata A, Zerbo M, Como S, Cammilleri M, Soresi M, Montalto G, Giannitrapani L. The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement? Nutrients 2021;13:4014. [PMID: 34836267 DOI: 10.3390/nu13114014] [Reference Citation Analysis]
10 Han CW, Kang ES, Ham SA, Woo HJ, Lee JH, Seo HG. Antioxidative effects of Alisma orientale extract in palmitate-induced cellular injury. Pharm Biol. 2012;50:1281-1288. [PMID: 22857151 DOI: 10.3109/13880209.2012.673629] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
11 Choi N, Kim JW, Jeong H, Shin DG, Seo JH, Kim JH, Lim CW, Han KM, Kim B. Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model. J Ginseng Res 2019;43:196-208. [PMID: 30962734 DOI: 10.1016/j.jgr.2017.10.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
12 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
13 Lionetti L, Mollica MP, Donizzetti I, Gifuni G, Sica R, Pignalosa A, Cavaliere G, Gaita M, De Filippo C, Zorzano A, Putti R. High-lard and high-fish-oil diets differ in their effects on function and dynamic behaviour of rat hepatic mitochondria. PLoS One 2014;9:e92753. [PMID: 24663492 DOI: 10.1371/journal.pone.0092753] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 10.9] [Reference Citation Analysis]
14 Zhang Y, Baker SS, Baker RD, Zhu R, Zhu L. Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PLoS One 2012;7:e51131. [PMID: 23300535 DOI: 10.1371/journal.pone.0051131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
15 Pessayre D, Fromenty B, Berson A, Robin MA, Lettéron P, Moreau R, Mansouri A. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44:34-87. [PMID: 21892896 DOI: 10.3109/03602532.2011.604086] [Cited by in Crossref: 158] [Cited by in F6Publishing: 137] [Article Influence: 14.4] [Reference Citation Analysis]
16 Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-järvinen H. Gene expression in human NAFLD. American Journal of Physiology-Gastrointestinal and Liver Physiology 2008;294:G1281-7. [DOI: 10.1152/ajpgi.00074.2008] [Cited by in Crossref: 242] [Cited by in F6Publishing: 244] [Article Influence: 17.3] [Reference Citation Analysis]
17 Song L, Liu J, Shi T, Zhang Y, Xin Z, Cao X, Yang J. Angiotensin‐(1‐7), the product of ACE2 ameliorates NAFLD by acting through its receptor Mas to regulate hepatic mitochondrial function and glycolipid metabolism. FASEB j 2020;34:16291-306. [DOI: 10.1096/fj.202001639r] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Ma M, Mu T. Anti-diabetic effects of soluble and insoluble dietary fibre from deoiled cumin in low-dose streptozotocin and high glucose-fat diet-induced type 2 diabetic rats. Journal of Functional Foods 2016;25:186-96. [DOI: 10.1016/j.jff.2016.05.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 14] [Article Influence: 5.2] [Reference Citation Analysis]
19 George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003;39:756-764. [PMID: 14568258 DOI: 10.1016/s0168-8278(03)00376-3] [Cited by in Crossref: 169] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
20 Samuel VT, Liu Z, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI. Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease. Journal of Biological Chemistry 2004;279:32345-53. [DOI: 10.1074/jbc.m313478200] [Cited by in Crossref: 892] [Cited by in F6Publishing: 457] [Article Influence: 49.6] [Reference Citation Analysis]
21 Baeder AC, Napa K, Richardson ST, Taylor OJ, Andersen SG, Wilcox SH, Winden DR, Reynolds PR, Bikman BT. Oral Gingival Cell Cigarette Smoke Exposure Induces Muscle Cell Metabolic Disruption. Int J Dent 2016;2016:2763160. [PMID: 27034671 DOI: 10.1155/2016/2763160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Suliman HM, Osman B, Abdoon IH, Saad AM, Khalid H. Ameliorative activity of Adansonia digitata fruit on high sugar/high fat diet-simulated Metabolic Syndrome model in male Wistar rats. Biomed Pharmacother 2020;125:109968. [PMID: 32066041 DOI: 10.1016/j.biopha.2020.109968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Yamada K, Mizukoshi E, Sunagozaka H, Arai K, Yamashita T, Takeshita Y, Misu H, Takamura T, Kitamura S, Zen Y, Nakanuma Y, Honda M, Kaneko S. Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis. Liver Int. 2015;35:582-590. [PMID: 25219574 DOI: 10.1111/liv.12685] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
24 Franzoni AC, Amorim AM, Silva JVMD, Storti JAP, Oliveira MCD. Use of Ursodeoxycholic Acid on Post-menopausal Obesity, Hepatic steatosis and Plasma Profile as an Alternative Treatment for Hormone Replacement Therapy. Braz arch biol technol 2015;58:898-904. [DOI: 10.1590/s1516-89132015060310] [Reference Citation Analysis]
25 Tamura S, Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1139-1142. [PMID: 15864343 DOI: 10.1172/jci200524930] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
26 Cazanave S, Podtelezhnikov A, Jensen K, Seneshaw M, Kumar DP, Min HK, Santhekadur PK, Banini B, Mauro AG, M Oseini A, Vincent R, Tanis KQ, Webber AL, Wang L, Bedossa P, Mirshahi F, Sanyal AJ. The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. Sci Rep 2017;7:17193. [PMID: 29222421 DOI: 10.1038/s41598-017-17370-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
27 Di Bonito P, Sanguigno E, Di Fraia T, Forziato C, Boccia G, Saitta F, Iardino MR, Capaldo B. Association of elevated serum alanine aminotransferase with metabolic factors in obese children: sex-related analysis. Metabolism 2009;58:368-72. [PMID: 19217453 DOI: 10.1016/j.metabol.2008.10.010] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
28 Xin YN, Geng N, Lin ZH, Cui YZ, Duan HP, Zhang M, Xuan SY. Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins. PLoS One 2014;9:e108132. [PMID: 25250770 DOI: 10.1371/journal.pone.0108132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
29 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038-48. [DOI: 10.1016/j.metabol.2015.12.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Sabbagha NG, Kao HJ, Yang CF, Huang CC, Lin WD, Tsai FJ, Chen TH, Tarn WY, Wu JY, Chen YT. Alternative splicing in Acad8 resulting a mitochondrial defect and progressive hepatic steatosis in mice. Pediatr Res 2011;70:31-6. [PMID: 21659959 DOI: 10.1203/PDR.0b013e31821b89ee] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
31 Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol 2014; 20(44): 16452-16463 [PMID: 25469013 DOI: 10.3748/wjg.v20.i44.16452] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 79] [Article Influence: 11.5] [Reference Citation Analysis]
32 Eiszrich Á, Fehér J. Fatty liver in childhood. Orvosi Hetilap 2007;148:2461-8. [DOI: 10.1556/oh.2007.28270] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Sun LF, Yang YL, Wang MY, Zhao HS, Xiao TX, Li MX, Wang BB, Huang C, Ren PG, Zhang JV. Inhibition of Col6a5 Improve Lipid Metabolism Disorder in Dihydrotestosterone-Induced Hyperandrogenic Mice. Front Cell Dev Biol 2021;9:669189. [PMID: 34109177 DOI: 10.3389/fcell.2021.669189] [Reference Citation Analysis]
34 van Ginneken VJ. Liver fattening during feast and famine: an evolutionary paradox. Med Hypotheses 2008;70:924-8. [PMID: 18054439 DOI: 10.1016/j.mehy.2007.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
35 Kim SW, Hur W, Li TZ, Lee YK, Choi JE, Hong SW, Lyoo KS, You CR, Jung ES, Jung CK, Park T, Um SJ, Yoon SK. Oleuropein prevents the progression of steatohepatitis to hepatic fibrosis induced by a high-fat diet in mice. Exp Mol Med 2014;46:e92. [PMID: 24763197 DOI: 10.1038/emm.2014.10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
36 Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol. 2013;379:35-42. [PMID: 23770462 DOI: 10.1016/j.mce.2013.06.002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 7.3] [Reference Citation Analysis]
37 Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson GT, Kahn JA, Malet PF, Sheikh MY, Chung RT. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol. 2006;101:983-992. [PMID: 16573786 DOI: 10.1111/j.1572-0241.2006.00461.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
38 Maffeis C, Manfredi R, Trombetta M, Sordelli S, Storti M, Benuzzi T, Bonadonna RC. Insulin sensitivity is correlated with subcutaneous but not visceral body fat in overweight and obese prepubertal children. J Clin Endocrinol Metab. 2008;93:2122-2128. [PMID: 18397988 DOI: 10.1210/jc.2007-2089] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 4.4] [Reference Citation Analysis]
39 Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663-678. [PMID: 12406438 DOI: 10.1053/bega.2002.0333] [Cited by in Crossref: 283] [Cited by in F6Publishing: 273] [Article Influence: 14.9] [Reference Citation Analysis]
40 Ægidius HM, Veidal SS, Feigh M, Hallenborg P, Puglia M, Pers TH, Vrang N, Jelsing J, Kornum BR, Blagoev B, Rigbolt KTG. Multi-omics characterization of a diet-induced obese model of non-alcoholic steatohepatitis. Sci Rep 2020;10:1148. [PMID: 31980690 DOI: 10.1038/s41598-020-58059-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
41 Chen JY, Chou CH, Tsai WC, Wang MC, Ho CS, Li YH, Tsai YS, Tsai LM. Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease. J Am Soc Hypertens. 2012;6:253-260. [PMID: 22651911 DOI: 10.1016/j.jash.2012.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
42 Lockman KA, Baren JP, Pemberton CJ, Baghdadi H, Burgess KE, Plevris-papaioannou N, Lee P, Howie F, Beckett G, Pryde A, Jaap AJ, Hayes PC, Filippi C, Plevris JN. Oxidative stress rather than triglyceride accumulation is a determinant of mitochondrial dysfunction in in vitro models of hepatic cellular steatosis. Liver Int 2012;32:1079-92. [DOI: 10.1111/j.1478-3231.2012.02775.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
43 Amin MA, Sabry D, Kassem M, Amin A. Effect of pentoxifylline on serum hyaluronic acid in patients with non-alcoholic fatty liver disease. Arab Journal of Gastroenterology 2009;10:102-5. [DOI: 10.1016/j.ajg.2009.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, Liu CJ, Wu MS, Shih SC. Nonalcoholic fatty liver disease: Updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol 2014; 20(24): 7718-7729 [PMID: 24976709 DOI: 10.3748/wjg.v20.i24.7718] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
45 Sumi T, Shirakami Y, Shimizu M, Kochi T, Ohno T, Kubota M, Shiraki M, Tsurumi H, Tanaka T, Moriwaki H. (-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis. Springerplus 2013;2:690. [PMID: 25674420 DOI: 10.1186/2193-1801-2-690] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
46 Nobili V, Alisi A, Raponi M. Pediatric non-alcoholic fatty liver disease: Preventive and therapeutic value of lifestyle intervention. World J Gastroenterol 2009; 15(48): 6017-6022 [PMID: 20027672 DOI: 10.3748/wjg.15.6017] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
47 Ji HF, Sun Y, Shen L. Effect of vitamin E supplementation on aminotransferase levels in patients with NAFLD, NASH, and CHC: results from a meta-analysis.Nutrition. 2014;30:986-991. [PMID: 24976430 DOI: 10.1016/j.nut.2014.01.016] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 5.1] [Reference Citation Analysis]
48 Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 2010;52:1836-46. [DOI: 10.1002/hep.24001] [Cited by in Crossref: 1281] [Cited by in F6Publishing: 1207] [Article Influence: 106.8] [Reference Citation Analysis]
49 Afonso MB, Rodrigues PM, Carvalho T, Caridade M, Borralho P, Cortez-Pinto H, Castro RE, Rodrigues CM. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin Sci (Lond). 2015;129:721-739. [PMID: 26201023 DOI: 10.1042/cs20140732] [Cited by in Crossref: 98] [Cited by in F6Publishing: 58] [Article Influence: 14.0] [Reference Citation Analysis]
50 Dall M, Trammell SAJ, Asping M, Hassing AS, Agerholm M, Vienberg SG, Gillum MP, Larsen S, Treebak JT. Mitochondrial function in liver cells is resistant to perturbations in NAD+ salvage capacity. J Biol Chem 2019;294:13304-26. [PMID: 31320478 DOI: 10.1074/jbc.RA118.006756] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
51 Koek G, Liedorp P, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clinica Chimica Acta 2011;412:1297-305. [DOI: 10.1016/j.cca.2011.04.013] [Cited by in Crossref: 202] [Cited by in F6Publishing: 195] [Article Influence: 18.4] [Reference Citation Analysis]
52 Sabag A, Little JP, Johnson NA. Low-volume high-intensity interval training for cardiometabolic health. J Physiol 2021. [PMID: 33760255 DOI: 10.1113/JP281210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
53 Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol 2006; 12(3): 345-353 [PMID: 16489632 DOI: 10.3748/wjg.v12.i3.345] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
54 Hilscher MB, Shah VH. Neutrophil Extracellular Traps and Liver Disease. Semin Liver Dis 2020;40:171-9. [PMID: 31726473 DOI: 10.1055/s-0039-3399562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
55 Traussnigg S, Kienbacher C, Gajdošík M, Valkovič L, Halilbasic E, Stift J, Rechling C, Hofer H, Steindl-Munda P, Ferenci P, Wrba F, Trattnig S, Krššák M, Trauner M. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis. Liver Int 2017;37:1544-53. [PMID: 28544208 DOI: 10.1111/liv.13451] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
56 Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol. 2002;16:733-747. [PMID: 12406442 DOI: 10.1053/bega.2002.0334] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.7] [Reference Citation Analysis]
57 Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146:726-735. [PMID: 24316260 DOI: 10.1053/j.gastro.2013.11.049] [Cited by in Crossref: 443] [Cited by in F6Publishing: 422] [Article Influence: 49.2] [Reference Citation Analysis]
58 De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4:375-385. [PMID: 20305757 DOI: 10.1007/s12072-009-9160-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
59 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(15): 1907-1909 [DOI: 10.11569/wcjd.v13.i15.1907] [Reference Citation Analysis]
60 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Reference Citation Analysis]
61 Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48:434-441. [PMID: 23397118 DOI: 10.1007/s00535-013-0758-5] [Cited by in Crossref: 427] [Cited by in F6Publishing: 408] [Article Influence: 47.4] [Reference Citation Analysis]
62 Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013;5:1544-60. [PMID: 23666091 DOI: 10.3390/nu5051544] [Cited by in Crossref: 406] [Cited by in F6Publishing: 378] [Article Influence: 45.1] [Reference Citation Analysis]
63 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
64 Liew PL, Lee WJ, Wang W, Lee YC, Chen WY, Fang CL, Huang MT. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity. Obes Surg. 2008;18:847-853. [PMID: 18459024 DOI: 10.1007/s11695-007-9355-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
65 Qi NR, Wang J, Zidek V, Landa V, Mlejnek P, Kazdová L, Pravenec M, Kurtz TW. A new transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension. 2005;45:1004-1011. [PMID: 15809359 DOI: 10.1161/01.hyp.0000161995.64192.2b] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
66 Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. Adv Med Sci. 2009;54:177-182. [PMID: 20022856 DOI: 10.2478/v10039-009-0047-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
67 Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, Komatsu M, Umemura T, Matsumoto A, Tanaka E. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol 2018; 24(13): 1440-1450 [PMID: 29632425 DOI: 10.3748/wjg.v24.i13.1440] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
68 Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F, Angelico F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005166.pub2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
69 Elshazly SM. Ameliorative effect of nicorandil on high fat diet induced non-alcoholic fatty liver disease in rats. European Journal of Pharmacology 2015;748:123-32. [DOI: 10.1016/j.ejphar.2014.12.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
70 Sumida Y, Yoneda M, Seko Y, Takahashi H, Hara N, Fujii H, Itoh Y, Yoneda M, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD). Role of vitamin E in the treatment of non-alcoholic steatohepatitis. Free Radic Biol Med 2021;177:391-403. [PMID: 34715296 DOI: 10.1016/j.freeradbiomed.2021.10.017] [Reference Citation Analysis]
71 Besse-Patin A, Estall JL. An Intimate Relationship between ROS and Insulin Signalling: Implications for Antioxidant Treatment of Fatty Liver Disease. Int J Cell Biol 2014;2014:519153. [PMID: 24672550 DOI: 10.1155/2014/519153] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
72 Ohmi S, Ono M, Takata H, Hirano S, Funakoshi S, Nishi Y, Yoshimura K, Amano E, Terada Y, Saibara T, Fujimoto S. Analysis of factors influencing glucose tolerance in Japanese patients with non-alcoholic fatty liver disease. Diabetol Metab Syndr 2017;9. [DOI: 10.1186/s13098-017-0264-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
73 Asaoka Y, Terai S, Sakaida I, Nishina H. The expanding role of fish models in understanding non-alcoholic fatty liver disease. Dis Model Mech. 2013;6:905-914. [PMID: 23720231 DOI: 10.1242/dmm.011981] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
74 Younossi ZM, Gramlich T, Matteoni CA, Boparai N, Mccullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology 2004;2:262-5. [DOI: 10.1016/s1542-3565(04)00014-x] [Cited by in Crossref: 259] [Cited by in F6Publishing: 92] [Article Influence: 14.4] [Reference Citation Analysis]
75 Sterling RK, Sanyal AJ. Pentoxifylline for steatohepatitis: magic bullet or smoking gun? Hepatology 2011;54:1496-9. [PMID: 22045667 DOI: 10.1002/hep.24612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
76 Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6:1-28. [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004] [Cited by in Crossref: 434] [Cited by in F6Publishing: 426] [Article Influence: 27.1] [Reference Citation Analysis]
77 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
78 Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-125. [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
79 Wang HN, Wang YR, Liu GQ, Liu Z, Wu PX, Wei XL, Hong TP. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14(47): 7240-7246 [PMID: 19084941 DOI: 10.3748/wjg.14.7240] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
80 Hogg K, Wood C, McNeilly AS, Duncan WC. The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep. PLoS One 2011;6:e24877. [PMID: 21935484 DOI: 10.1371/journal.pone.0024877] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 5.0] [Reference Citation Analysis]
81 Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2011;23:382-388. [PMID: 21448070 DOI: 10.1097/MEG.0b013e328345c8c7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
82 Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2009;19:291-302. [PMID: 19359149 DOI: 10.1016/j.numecd.2008.12.015] [Cited by in Crossref: 197] [Cited by in F6Publishing: 189] [Article Influence: 15.2] [Reference Citation Analysis]
83 Spahis S, Alvarez F, Ahmed N, Dubois J, Jalbout R, Paganelli M, Grzywacz K, Delvin E, Peretti N, Levy E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids. The Journal of Nutritional Biochemistry 2018;58:28-36. [DOI: 10.1016/j.jnutbio.2018.03.025] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
84 Szendroedi J, Chmelik M, Schmid AI, Nowotny P, Brehm A, Krssak M, Moser E, Roden M. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 2009;50:1079-86. [PMID: 19637187 DOI: 10.1002/hep.23093] [Cited by in Crossref: 126] [Cited by in F6Publishing: 114] [Article Influence: 9.7] [Reference Citation Analysis]
85 Svop Jensen V, Fledelius C, Max Wulff E, Lykkesfeldt J, Hvid H. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet. Nutrients 2021;13:604. [PMID: 33673227 DOI: 10.3390/nu13020604] [Reference Citation Analysis]
86 Fujibayashi K, Gunji T, Yokokawa H, Naito T, Sasabe N, Okumura M, Iijima K, Shibuya K, Hisaoka T, Fukuda H. The Relationships between Metabolic Disorders (Hypertension, Dyslipidemia, and Impaired Glucose Tolerance) and Computed Tomography-Based Indices of Hepatic Steatosis or Visceral Fat Accumulation in Middle-Aged Japanese Men. PLoS One 2016;11:e0149689. [PMID: 26938785 DOI: 10.1371/journal.pone.0149689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
87 Bertola A, Deveaux V, Bonnafous S, Rousseau D, Anty R, Wakkach A, Dahman M, Tordjman J, Clément K, McQuaid SE, Frayn KN, Huet PM, Gugenheim J, Lotersztajn S, Le Marchand-Brustel Y, Tran A, Gual P. Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity. Diabetes 2009;58:125-33. [PMID: 18952835 DOI: 10.2337/db08-0400] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 6.8] [Reference Citation Analysis]
88 Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-tainturier M, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93. [DOI: 10.1053/jhep.2002.33324] [Cited by in Crossref: 329] [Cited by in F6Publishing: 302] [Article Influence: 17.3] [Reference Citation Analysis]
89 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
90 Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004;40:47-51. [PMID: 14672613 DOI: 10.1016/j.jhep.2003.09.020] [Cited by in Crossref: 288] [Cited by in F6Publishing: 276] [Article Influence: 16.0] [Reference Citation Analysis]
91 Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008;28:360-369. [PMID: 18956292 DOI: 10.1055/s-0028-1091980] [Cited by in Crossref: 346] [Cited by in F6Publishing: 339] [Article Influence: 24.7] [Reference Citation Analysis]
92 Willmes DM, Kurzbach A, Henke C, Schumann T, Zahn G, Heifetz A, Jordan J, Helfand SL, Birkenfeld AL. The longevity gene INDY ( I 'm N ot D ead Y et) in metabolic control: Potential as pharmacological target. Pharmacology & Therapeutics 2018;185:1-11. [DOI: 10.1016/j.pharmthera.2017.10.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
93 Muñoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in a group of mexican patients with nonalcoholic steatohepatitis. Annals of Hepatology 2009;8:123-8. [DOI: 10.1016/s1665-2681(19)31790-9] [Cited by in Crossref: 14] [Article Influence: 1.1] [Reference Citation Analysis]
94 Belia S, Lupattelli G, Urbani E, Vaudo G, Roscini AR, Perni S, Marsili V. Oxidative balance in lymphocytes from patients with nonalcoholic steatohepatitis. Am J Med Sci 2014;348:30-6. [PMID: 24949725 DOI: 10.1097/MAJ.0000000000000191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
95 Yan X, Xu L, Qi J, Liang X, Ma C, Guo C, Zhang L, Sun W, Zhang J, Wei X. sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics. 2009;61:551-556. [PMID: 19629467 DOI: 10.1007/s00251-009-0389-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
96 Wang Y, Zhao L, Wang D, Huo Y, Ji B. Anthocyanin-rich extracts from blackberry, wild blueberry, strawberry, and chokeberry: antioxidant activity and inhibitory effect on oleic acid-induced hepatic steatosis in vitro. J Sci Food Agric 2016;96:2494-503. [PMID: 26250597 DOI: 10.1002/jsfa.7370] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
97 Kim JH, Lee HS, Park HM, Lee YJ. Serum alkaline phosphatase level is positively associated with metabolic syndrome: A nationwide population-based study. Clin Chim Acta 2020;500:189-94. [PMID: 31678575 DOI: 10.1016/j.cca.2019.10.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
98 Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem. 2010;43:815-821. [PMID: 20398645 DOI: 10.1016/j.clinbiochem.2010.04.003] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
99 Suh S, Choi S, Ahn H, Yang H, Kim Y, Sung N. The association between normal alanine aminotransferase levels and the metabolic syndrome: 2005 Korean National Health and Nutrition Examination Survey. Metabolism 2009;58:1731-6. [DOI: 10.1016/j.metabol.2009.05.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
100 Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. Ann Surg. 2007;245:20-30. [PMID: 17197961 DOI: 10.1097/01.sla.0000225113.88433.cf] [Cited by in Crossref: 193] [Cited by in F6Publishing: 183] [Article Influence: 12.9] [Reference Citation Analysis]
101 Mueller M, Castro RE, Thorell A, Marschall HU, Auer N, Herac M, Rodrigues CMP, Trauner M. Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. Liver Int 2018;38:523-31. [PMID: 28853202 DOI: 10.1111/liv.13562] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
102 Liu Y, Lu J, Xu M, Xu Y, Li M, Wang T, Zhang J, Xu B, Sun J, Dai M, Bi Y, Wang W, Ning G. Association between history of abortion and nonalcoholic fatty liver disease in middle-aged and elderly Chinese women. Ann Epidemiol 2013;23:119-23. [PMID: 23298439 DOI: 10.1016/j.annepidem.2012.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
103 Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Practice & Research Clinical Gastroenterology 2002;16:691-707. [DOI: 10.1053/bega.2002.0326] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
104 Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, Nakamura T, Teranishi H, Mizusawa S, Ueno T, Chayama K, Nakajima A, Nakao K, Sekine A, Hotta K. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet. 2013;132:783-792. [PMID: 23535911 DOI: 10.1007/s00439-013-1294-3] [Cited by in Crossref: 113] [Cited by in F6Publishing: 108] [Article Influence: 12.6] [Reference Citation Analysis]
105 Kurt YG, Cayci T, Akgul EO, Cakir E. Indicators of mitochondrial disease. Sao Paulo Med J 2013;131:64-5. [PMID: 23538599 DOI: 10.1590/s1516-31802013000100012] [Reference Citation Analysis]
106 Hodson L, Gunn PJ. The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state. Nat Rev Endocrinol 2019;15:689-700. [DOI: 10.1038/s41574-019-0256-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
107 Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2004;19:537-544. [PMID: 14987322 DOI: 10.1111/j.1365-2036.2004.01888.x] [Cited by in Crossref: 280] [Cited by in F6Publishing: 253] [Article Influence: 15.6] [Reference Citation Analysis]
108 Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol. 2008;294:G27-G38. [PMID: 17947452 DOI: 10.1152/ajpgi.00296.2007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 6.0] [Reference Citation Analysis]
109 Selen ES, Choi J, Wolfgang MJ. Discordant hepatic fatty acid oxidation and triglyceride hydrolysis leads to liver disease. JCI Insight 2021;6:135626. [PMID: 33491665 DOI: 10.1172/jci.insight.135626] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
110 Piperno A, Trombini P, Gelosa M, Mauri V, Pecci V, Vergani A, Salvioni A, Mariani R, Mancia G. Increased serum ferritin is common in men with essential hypertension. J Hypertens. 2002;20:1513-1518. [PMID: 12172312 DOI: 10.1097/00004872-200208000-00013] [Cited by in Crossref: 118] [Cited by in F6Publishing: 101] [Article Influence: 6.2] [Reference Citation Analysis]
111 Flamment M, Kammoun HL, Hainault I, Ferré P, Foufelle F. Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis. Curr Opin Lipidol. 2010;21:239-246. [PMID: 20463471 DOI: 10.1097/mol.0b013e3283395e5c] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
112 Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008;48:300-307. [PMID: 18086506 DOI: 10.1016/j.jhep.2007.09.009] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 9.7] [Reference Citation Analysis]
113 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 392] [Cited by in F6Publishing: 366] [Article Influence: 30.2] [Reference Citation Analysis]
114 Greaves P. Liver and Pancreas. Histopathology of Preclinical Toxicity Studies. Elsevier; 2012. pp. 433-535. [DOI: 10.1016/b978-0-444-53856-7.00009-9] [Cited by in Crossref: 8] [Article Influence: 0.8] [Reference Citation Analysis]
115 Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease: REVIEW: PAEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE. Alimentary Pharmacology & Therapeutics 2008;28:13-24. [DOI: 10.1111/j.1365-2036.2008.03703.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
116 Fon Tacer K, Rozman D. Nonalcoholic Fatty liver disease: focus on lipoprotein and lipid deregulation. J Lipids. 2011;2011:783976. [PMID: 21773052 DOI: 10.1155/2011/783976] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 9.0] [Reference Citation Analysis]
117 Renaud HJ, Cui JY, Lu H, Klaassen CD. Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis. PLoS One 2014;9:e88584. [PMID: 24551121 DOI: 10.1371/journal.pone.0088584] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 7.8] [Reference Citation Analysis]
118 Sardana O, Goyal R, Bedi O. Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD. Inflammopharmacology 2021;29:1061-74. [PMID: 34185201 DOI: 10.1007/s10787-021-00837-4] [Reference Citation Analysis]
119 García-Ruiz I, Rodríguez-Juan C, Díaz-Sanjuan T, del Hoyo P, Colina F, Muñoz-Yagüe T, Solís-Herruzo JA. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 2006;44:581-91. [PMID: 16941682 DOI: 10.1002/hep.21313] [Cited by in Crossref: 134] [Cited by in F6Publishing: 131] [Article Influence: 8.4] [Reference Citation Analysis]
120 Kim EJ, Kim BH, Seo HS, Lee YJ, Kim HH, Son HH, Choi MH. Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PLoS One 2014;9:e97841. [PMID: 24901254 DOI: 10.1371/journal.pone.0097841] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
121 Mitsinikos T, Mrowczynski-Hernandez P, Kohli R. Pediatric Nonalcoholic Fatty Liver Disease. Pediatr Clin North Am 2021;68:1309-20. [PMID: 34736591 DOI: 10.1016/j.pcl.2021.07.013] [Reference Citation Analysis]
122 Minakari M, Sameni FK, Shalmani HM, Molaee M, Zali MR. Hepatic steatosis in Iranian patients with chronic hepatitis C. Med Princ Pract 2008;17:126-30. [PMID: 18287796 DOI: 10.1159/000112966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
123 dela Peña A, Leclercq I, Field J, George J, Jones B, Farrell G. NF-κB Activation, Rather Than TNF, Mediates Hepatic Inflammation in a Murine Dietary Model of Steatohepatitis. Gastroenterology 2005;129:1663-74. [DOI: 10.1053/j.gastro.2005.09.004] [Cited by in Crossref: 200] [Cited by in F6Publishing: 202] [Article Influence: 11.8] [Reference Citation Analysis]
124 Wang X, Cao Y, Fu Y, Guo G, Zhang X. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease. Lipids Health Dis 2011;10:234. [PMID: 22165986 DOI: 10.1186/1476-511X-10-234] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
125 Morris EM, Rector RS, Thyfault JP, Ibdah JA. Mitochondria and redox signaling in steatohepatitis. Antioxid Redox Signal 2011;15:485-504. [PMID: 21128703 DOI: 10.1089/ars.2010.3795] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
126 Zhao J, van Mierlo KMC, Gómez-Ramírez J, Kim H, Pilgrim CHC, Pessaux P, Rensen SS, van der Stok EP, Schaap FG, Soubrane O, Takamoto T, Viganò L, Winkens B, Dejong CHC, Olde Damink SWM; Chemotherapy-Associated Liver Injury (CALI) consortium. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg 2017;104:990-1002. [PMID: 28542731 DOI: 10.1002/bjs.10572] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
127 Malaguarnera L, Di Rosa M, Zambito AM, dell’Ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut. 2006;55:1313-1320. [PMID: 16825325 DOI: 10.1136/gut.2005.075697] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 4.2] [Reference Citation Analysis]
128 Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081-1090. [PMID: 17654743 DOI: 10.1002/hep.21763] [Cited by in Crossref: 776] [Cited by in F6Publishing: 733] [Article Influence: 51.7] [Reference Citation Analysis]
129 Ajaz S, McPhail MJ, Gnudi L, Trovato FM, Mujib S, Napoli S, Carey I, Agarwal K. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion 2021;57:119-30. [PMID: 33387664 DOI: 10.1016/j.mito.2020.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
130 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219. [PMID: 12717402 DOI: 10.1053/jhep.2003.50193] [Cited by in Crossref: 1410] [Cited by in F6Publishing: 1313] [Article Influence: 74.2] [Reference Citation Analysis]
131 Che DN, Shin JY, Kang HJ, Cho BO, Park JH, Wang F, Hao S, Sim JS, Sim DJ, Jang SI. Ameliorative effects of Cirsium japonicum extract and main component cirsimaritin in mice model of high-fat diet-induced metabolic dysfunction-associated fatty liver disease. Food Sci Nutr 2021;9:6060-8. [PMID: 34760237 DOI: 10.1002/fsn3.2548] [Reference Citation Analysis]
132 Sinha SK, Bhangoo A, Anhalt H, Maclaren N, Marshall JD, Collin GB, Naggert JK, Ten S. Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome. J Pediatr Endocrinol Metab 2007;20:1045-52. [PMID: 18038714 DOI: 10.1515/jpem.2007.20.9.1045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
133 Ogawa Y, Yoneda M, Kobayashi T, Honda Y, Kessoku T, Imajo K, Saito S, Nakajima A. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2018;20:69-82. [DOI: 10.1080/14656566.2018.1543403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
134 Müller C, Gardemann A, Keilhoff G, Peter D, Wiswedel I, Kropf S, Schild L. Palmitate protects hepatocytes from oxidative stress and triacylglyceride accumulation by stimulation of nitric oxide synthesis in the presence of high glucose and insulin concentration. Free Radical Research 2010;44:1425-34. [DOI: 10.3109/10715762.2010.512919] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
135 Chen X, Zhang Z, Cui B, Jiang A, Tao H, Cheng S, Liu Y. Combination of Chronic Alcohol Consumption and High-Salt Intake Elicits Gut Microbial Alterations and Liver Steatosis in Mice. J Agric Food Chem 2020;68:1750-9. [PMID: 31971384 DOI: 10.1021/acs.jafc.9b07368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002;17 Suppl 3:S377-S384. [PMID: 12472967 DOI: 10.1046/j.1440-1746.17.s3.31.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 7.4] [Reference Citation Analysis]
137 Scheen A, Luyckx F. NONALCOHOLIC STEATOHEPATITIS AND INSULIN RESISTANCE : INTERFACE BETWEEN GASTROENTEROLOGISTS AND ENDOCRINOLOGISTS. Acta Clinica Belgica 2014;58:106-16. [DOI: 10.1179/acb.2003.58.2.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
138 André P, Balkau B, Born C, Royer B, Wilpart E, Charles MA, Eschwège E. Hepatic markers and development of type 2 diabetes in middle aged men and women: a three-year follow-up study. The D.E.S.I.R. Study (Data from an Epidemiological Study on the Insulin Resistance syndrome). Diabetes Metab. 2005;31:542-550. [PMID: 16357802 DOI: 10.1016/s1262-3636(07)70229-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
139 Pattullo V, Douglas MW, George J. Organelle dysfunction in hepatitis C virus-associated steatosis: anything to learn from nonalcoholic steatohepatitis? Expert Rev Gastroenterol Hepatol 2011;5:265-77. [PMID: 21476921 DOI: 10.1586/egh.11.12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
140 Hijmans BS, Grefhorst A, Oosterveer MH, Groen AK. Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences. Biochimie. 2014;96:121-129. [PMID: 23792151 DOI: 10.1016/j.biochi.2013.06.007] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 10.6] [Reference Citation Analysis]
141 Hotta K, Kitamoto T, Kitamoto A, Ogawa Y, Honda Y, Kessoku T, Yoneda M, Imajo K, Tomeno W, Saito S, Nakajima A. Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression. Hepatol Res 2018;48:E320-34. [PMID: 29059699 DOI: 10.1111/hepr.12992] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
142 Lim HW, Bernstein DE. Risk Factors for the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Genetics. Clin Liver Dis 2018;22:39-57. [PMID: 29128060 DOI: 10.1016/j.cld.2017.08.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
143 Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Nakashima M, Nakamuta M. The effects of unsaturated fatty acids on lipid metabolism in HepG2 cells. In Vitro Cell Dev Biol -Animal 2009;45:6-9. [DOI: 10.1007/s11626-008-9144-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
144 Bell LN, Molleston JP, Morton MJ, Klipsch A, Saxena R, Vuppalanchi R, Chalasani N. Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes. J Clin Gastroenterol. 2011;45:800-807. [PMID: 21602702 DOI: 10.1097/mcg.0b013e31821377e4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
145 Kim HJ, Han YH, Na H, Kim JY, Kim T, Kim HJ, Shin C, Lee JW, Lee MO. Liver-specific deletion of RORα aggravates diet-induced nonalcoholic steatohepatitis by inducing mitochondrial dysfunction. Sci Rep 2017;7:16041. [PMID: 29167529 DOI: 10.1038/s41598-017-16077-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
146 Azzimato V, Chen P, Barreby E, Morgantini C, Levi L, Vankova A, Jager J, Sulen A, Diotallevi M, Shen JX, Miller A, Ellis E, Rydén M, Näslund E, Thorell A, Lauschke VM, Channon KM, Crabtree MJ, Haschemi A, Craige SM, Mori M, Spallotta F, Aouadi M. Hepatic miR-144 Drives Fumarase Activity Preventing NRF2 Activation During Obesity. Gastroenterology 2021:S0016-5085(21)03410-7. [PMID: 34425095 DOI: 10.1053/j.gastro.2021.08.030] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Smith B, George J. Adipocyte-hepatocyte crosstalk and the pathogenesis of nonalcoholic fatty liver disease. Hepatology 2009;49:1765-7. [PMID: 19402105 DOI: 10.1002/hep.22937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
148 Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, Finch J, Gastaldelli A, Harrison S, Tio F, Cusi K. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-97. [PMID: 22183689 DOI: 10.1002/hep.25539] [Cited by in Crossref: 230] [Cited by in F6Publishing: 212] [Article Influence: 23.0] [Reference Citation Analysis]
149 Hong SH, Choi KM. Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. Int J Mol Sci 2020;21:E494. [PMID: 31941015 DOI: 10.3390/ijms21020494] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
150 Sahai A, Malladi P, Melin-aldana H, Green RM, Whitington PF. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. American Journal of Physiology-Gastrointestinal and Liver Physiology 2004;287:G264-73. [DOI: 10.1152/ajpgi.00002.2004] [Cited by in Crossref: 137] [Cited by in F6Publishing: 133] [Article Influence: 7.6] [Reference Citation Analysis]
151 Fritsch M, Koliaki C, Livingstone R, Phielix E, Bierwagen A, Meisinger M, Jelenik T, Strassburger K, Zimmermann S, Brockmann K, Wolff C, Hwang JH, Szendroedi J, Roden M. Time course of postprandial hepatic phosphorus metabolites in lean, obese, and type 2 diabetes patients. Am J Clin Nutr 2015;102:1051-8. [PMID: 26423389 DOI: 10.3945/ajcn.115.107599] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
152 Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53:1020-1023. [PMID: 15194655 DOI: 10.1136/gut.2003.027086] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 8.4] [Reference Citation Analysis]
153 Baker PR 2nd, Friedman JE. Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease. J Clin Invest 2018;128:3692-703. [PMID: 30168806 DOI: 10.1172/JCI120846] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
154 Li X, Wang R, Zhou N, Wang X, Liu Q, Bai Y, Bai Y, Liu Z, Yang H, Zou J, Wang H, Shi T. Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model. Biomed Rep 2013;1:71-6. [PMID: 24648896 DOI: 10.3892/br.2012.27] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
155 Davidson MD, Lehrer M, Khetani SR. Hormone and Drug-Mediated Modulation of Glucose Metabolism in a Microscale Model of the Human Liver. Tissue Eng Part C Methods 2015;21:716-25. [PMID: 25517416 DOI: 10.1089/ten.TEC.2014.0512] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
156 Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone A, Bagni A, Bertolotti M, Ganazzi D, Carulli N. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002;34:204-11. [DOI: 10.1016/s1590-8658(02)80194-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
157 Miele L, Grieco A, Armuzzi A, Candelli M, Forgione A, Gasbarrini A, Gasbarrini G. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol. 2003;98:2335-2336. [PMID: 14572600 DOI: 10.1111/j.1572-0241.2003.07725.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 4.3] [Reference Citation Analysis]
158 Ioannou GN, Weiss NS, Boyko EJ, Kowdley KV, Kahn SE, Carithers RL, Tsai EC, Dominitz JA. Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. Clinical Gastroenterology and Hepatology 2005;3:67-74. [DOI: 10.1016/s1542-3565(04)00442-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
159 Ghareeb DA, Hafez HS, Hussien HM, Kabapy NF. Non-alcoholic fatty liver induces insulin resistance and metabolic disorders with development of brain damage and dysfunction. Metab Brain Dis. 2011;26:253-267. [PMID: 21881966 DOI: 10.1007/s11011-011-9261-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
160 Kotronen A, Seppälä-Lindroos A, Vehkavaara S, Bergholm R, Frayn KN, Fielding BA, Yki-Järvinen H. Liver fat and lipid oxidation in humans. Liver Int 2009;29:1439-46. [PMID: 19602132 DOI: 10.1111/j.1478-3231.2009.02076.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 4.8] [Reference Citation Analysis]
161 Correia MA, Kwon D. Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models. Biology (Basel) 2020;9:E419. [PMID: 33255949 DOI: 10.3390/biology9120419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Chen J, Liu J, Wang Y, Hu X, Zhou F, Hu Y, Yuan Y, Xu Y. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro. Biomed Pharmacother 2017;91:621-31. [PMID: 28486193 DOI: 10.1016/j.biopha.2017.04.125] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
163 Cazanave SC, Mott JL, Elmi NA, Bronk SF, Werneburg NW, Akazawa Y, Kahraman A, Garrison SP, Zambetti GP, Charlton MR, Gores GJ. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem 2009;284:26591-602. [PMID: 19638343 DOI: 10.1074/jbc.M109.022491] [Cited by in Crossref: 148] [Cited by in F6Publishing: 99] [Article Influence: 11.4] [Reference Citation Analysis]
164 Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterology 2003;98:926-30. [DOI: 10.1111/j.1572-0241.2003.07375.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
165 Meex RCR, Blaak EE. Mitochondrial Dysfunction is a Key Pathway that Links Saturated Fat Intake to the Development and Progression of NAFLD. Mol Nutr Food Res 2021;65:e1900942. [PMID: 32574416 DOI: 10.1002/mnfr.201900942] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
166 Shimizu Y, Tamura T, Kemmochi A, Owada Y, Ozawa Y, Hisakura K, Matsuzaka T, Shimano H, Nakano N, Sakashita S, Oda T, Ohkohchi N. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2021;36:800-10. [PMID: 32870526 DOI: 10.1111/jgh.15239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
167 Coilly A, Desterke C, Guettier C, Samuel D, Chiappini F. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019;9:19785. [PMID: 31874999 DOI: 10.1038/s41598-019-56235-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
168 George J, Liddle C. Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets. Mol Pharmaceutics 2008;5:49-59. [DOI: 10.1021/mp700110z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 3.7] [Reference Citation Analysis]
169 Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res 2011;44:652-9. [DOI: 10.1590/s0100-879x2011007500083] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
170 Leclercq IA, Horsmans Y. Nonalcoholic fatty liver disease: the potential role of nutritional management. Curr Opin Clin Nutr Metab Care 2008;11:766-73. [PMID: 18827582 DOI: 10.1097/MCO.0b013e328312c353] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
171 Quiles JL, Pamplona R, Ramirez-tortosa MC, Naudí A, Portero-otin M, Araujo-nepomuceno E, López-frías M, Battino M, Ochoa JJ. Coenzyme Q addition to an n-6 PUFA-rich diet resembles benefits on age-related mitochondrial DNA deletion and oxidative stress of a MUFA-rich diet in rat heart. Mechanisms of Ageing and Development 2010;131:38-47. [DOI: 10.1016/j.mad.2009.11.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
172 Giammanco M, Di Liegro CM, Schiera G, Di Liegro I. Genomic and Non-Genomic Mechanisms of Action of Thyroid Hormones and Their Catabolite 3,5-Diiodo-L-Thyronine in Mammals. Int J Mol Sci 2020;21:E4140. [PMID: 32532017 DOI: 10.3390/ijms21114140] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
173 Bell LN, Temm CJ, Saxena R, Vuppalanchi R, Schauer P, Rabinovitz M, Krasinskas A, Chalasani N, Mattar SG. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann Surg. 2010;251:1041-1048. [PMID: 20485142 DOI: 10.1097/sla.0b013e3181dbb572] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
174 Caldwell SH, Patrie JT, Brunt EM, Redick JA, Davis CA, Park SH, Neuschwander-tetri BA. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology 2007;46:1101-7. [DOI: 10.1002/hep.21813] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
175 Grattagliano I, Palmieri VO, Portincasa P, Moschetta A, Palasciano G. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008;19:491-504. [PMID: 17855068 DOI: 10.1016/j.jnutbio.2007.06.011] [Cited by in Crossref: 189] [Cited by in F6Publishing: 166] [Article Influence: 12.6] [Reference Citation Analysis]
176 Periasamy S, Chien SP, Chang PC, Hsu DZ, Liu MY. Sesame oil mitigates nutritional steatohepatitis via attenuation of oxidative stress and inflammation: a tale of two-hit hypothesis. J Nutr Biochem 2014;25:232-40. [PMID: 24445049 DOI: 10.1016/j.jnutbio.2013.10.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
177 Adams LA, Knuiman MW, Divitini ML, Olynyk JK. Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. J Gastroenterol Hepatol 2008;23:1089-93. [PMID: 18557801 DOI: 10.1111/j.1440-1746.2008.05451.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
178 Wu N, Siow YL, O K. Induction of hepatic cyclooxygenase-2 by hyperhomocysteinemia via nuclear factor-κB activation. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2009;297:R1086-94. [DOI: 10.1152/ajpregu.00293.2009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
179 Song BJ, Akbar M, Jo I, Hardwick JP, Abdelmegeed MA. Translational Implications of the Alcohol-Metabolizing Enzymes, Including Cytochrome P450-2E1, in Alcoholic and Nonalcoholic Liver Disease. Adv Pharmacol 2015;74:303-72. [PMID: 26233911 DOI: 10.1016/bs.apha.2015.04.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
180 Vittal A, Shapses M, Sharma B, Sharma D, Sun Q, Sampson M, Lee W, Ben Yakov G, Rotman Y. Lipoprotein Insulin Resistance Index Reflects Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021;5:589-97. [PMID: 33860117 DOI: 10.1002/hep4.1658] [Reference Citation Analysis]
181 Li X, Liu L, Li R, Wu A, Lu J, Wu Q, Jia J, Zhao M, Song H. Hepatic loss of Lissencephaly 1 (Lis1) induces fatty liver and accelerates liver tumorigenesis in mice. J Biol Chem 2018;293:5160-71. [PMID: 29475944 DOI: 10.1074/jbc.RA117.001474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
182 Ma X, McKeen T, Zhang J, Ding WX. Role and Mechanisms of Mitophagy in Liver Diseases. Cells 2020;9:E837. [PMID: 32244304 DOI: 10.3390/cells9040837] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
183 Capeau J. Insulin resistance and steatosis in humans. Diabetes & Metabolism 2008;34:649-57. [DOI: 10.1016/s1262-3636(08)74600-7] [Cited by in Crossref: 76] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
184 Nomoto K, Tsuneyama K, Takahashi H, Murai Y, Takano Y. Cytoplasmic fine granular expression of 8-hydroxydeoxyguanosine reflects early mitochondrial oxidative DNA damage in nonalcoholic fatty liver disease. Appl Immunohistochem Mol Morphol. 2008;16:71-75. [PMID: 18091316 DOI: 10.1097/pai.0b013e31803156d5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
185 Walle P, Takkunen M, Männistö V, Vaittinen M, Lankinen M, Kärjä V, Käkelä P, Ågren J, Tiainen M, Schwab U, Kuusisto J, Laakso M, Pihlajamäki J. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity. Metabolism 2016;65:655-66. [PMID: 27085774 DOI: 10.1016/j.metabol.2016.01.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
186 Barr J, Caballería J, Martínez-Arranz I, Domínguez-Díez A, Alonso C, Muntané J, Pérez-Cormenzana M, García-Monzón C, Mayo R, Martín-Duce A, Romero-Gómez M, Lo Iacono O, Tordjman J, Andrade RJ, Pérez-Carreras M, Le Marchand-Brustel Y, Tran A, Fernández-Escalante C, Arévalo E, García-Unzueta M, Clement K, Crespo J, Gual P, Gómez-Fleitas M, Martínez-Chantar ML, Castro A, Lu SC, Vázquez-Chantada M, Mato JM. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 2012;11:2521-32. [PMID: 22364559 DOI: 10.1021/pr201223p] [Cited by in Crossref: 125] [Cited by in F6Publishing: 117] [Article Influence: 12.5] [Reference Citation Analysis]
187 Babu AF, Csader S, Lok J, Gómez-Gallego C, Hanhineva K, El-Nezami H, Schwab U. Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis. Nutrients 2021;13:3135. [PMID: 34579012 DOI: 10.3390/nu13093135] [Reference Citation Analysis]
188 Abruzzese GA, Heber MF, Ferrer MJ, Ferreira SR, Silva AF, Motta AB. Effects of in utero androgen excess and metformin treatment on hepatic functions. Mol Cell Endocrinol 2019;491:110416. [PMID: 30880153 DOI: 10.1016/j.mce.2019.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
189 Tanner MS. Mechanisms of liver injury relevant to pediatric hepatology. Crit Rev Clin Lab Sci. 2002;39:1-61. [PMID: 11890207 DOI: 10.1080/10408360290795439] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
190 Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820-826. [PMID: 15382171 DOI: 10.1002/hep.20410] [Cited by in Crossref: 45] [Cited by in F6Publishing: 128] [Article Influence: 2.5] [Reference Citation Analysis]
191 van Eyk HJ, Blauw LL, Bizino MB, Wang Y, van Dijk KW, de Mutsert R, Smit JWA, Lamb HJ, Jazet IM, Rensen PCN. Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort. Sci Rep 2019;9:9996. [PMID: 31292457 DOI: 10.1038/s41598-019-45593-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 de Luis D, Aller R, Izaola O, Gonzalez Sagrado M, Conde R, Gonzalez J. Effect of a hypocaloric diet in transaminases in nonalcoholic fatty liver disease and obese patients, relation with insulin resistance. Diabetes Research and Clinical Practice 2008;79:74-8. [DOI: 10.1016/j.diabres.2007.07.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
193 Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380-388. [PMID: 19501927 DOI: 10.1016/j.jhep.2009.03.025] [Cited by in Crossref: 188] [Cited by in F6Publishing: 182] [Article Influence: 14.5] [Reference Citation Analysis]
194 Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-597. [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020] [Cited by in Crossref: 318] [Cited by in F6Publishing: 297] [Article Influence: 17.7] [Reference Citation Analysis]
195 Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord. 2015;14:44. [PMID: 25995986 DOI: 10.1186/s40200-015-0170-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
196 Ruhl CE, Everhart JE. Relation of elevated serum alanine aminotransferase activity with iron and antioxidant levels in the United States. Gastroenterology 2003;124:1821-9. [DOI: 10.1016/s0016-5085(03)00395-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
197 Williams AS, Kang L, Zheng J, Grueter C, Bracy DP, James FD, Pozzi A, Wasserman DH. Integrin α1-null mice exhibit improved fatty liver when fed a high fat diet despite severe hepatic insulin resistance. J Biol Chem 2015;290:6546-57. [PMID: 25593319 DOI: 10.1074/jbc.M114.615716] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
198 Martin-benitez G, Marti-bonmati L, Barber C, Vila R. Hepatic lipomas and steatosis: An association beyond chance. European Journal of Radiology 2012;81:e491-4. [DOI: 10.1016/j.ejrad.2011.06.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Stinkens R, Goossens GH, Jocken JWE, Blaak EE. Targeting fatty acid metabolism to improve glucose metabolism: Targeting fatty acid metabolism. Obes Rev 2015;16:715-57. [DOI: 10.1111/obr.12298] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 11.3] [Reference Citation Analysis]
200 Silva GH, Hessel G, Coelho KIR, Escanhoela CAF. Steatosis of indeterminate cause in a pediatric group: is it a primary mitochondrial hepatopathy? Sao Paulo Med J 2011;129:217-23. [DOI: 10.1590/s1516-31802011000400004] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
201 Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem. 2005;280:9887-9894. [PMID: 15632182 DOI: 10.1074/jbc.m410310200] [Cited by in Crossref: 144] [Cited by in F6Publishing: 66] [Article Influence: 8.5] [Reference Citation Analysis]
202 Kumar A, Sharma A, Duseja A, Das A, Dhiman RK, Chawla YK, Kohli KK, Bhansali A. Patients with Nonalcoholic Fatty Liver Disease (NAFLD) have Higher Oxidative Stress in Comparison to Chronic Viral Hepatitis. J Clin Exp Hepatol 2013;3:12-8. [PMID: 25755466 DOI: 10.1016/j.jceh.2012.10.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
203 Carabelli J, Burgueño AL, Rosselli MS, Gianotti TF, Lago NR, Pirola CJ, Sookoian S. High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J Cell Mol Med 2011;15:1329-38. [PMID: 20629985 DOI: 10.1111/j.1582-4934.2010.01128.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 5.5] [Reference Citation Analysis]
204 Liu YW, Hui HY, Tan ZJ. Effect of edible oil on health: Relationship with intestinal microflora. Shijie Huaren Xiaohua Zazhi 2019; 27(9): 583-588 [DOI: 10.11569/wcjd.v27.i9.583] [Reference Citation Analysis]
205 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
206 Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, Celebi S, Ustundag B, Ozercan IH, Sahin K. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol. 2007;22:2009-2014. [PMID: 17914984 DOI: 10.1111/j.1440-1746.2006.04681.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
207 Liang H, Zhang L, Wang H, Tang J, Yang J, Wu C, Chen S. Inhibitory Effect of Gardenoside on Free Fatty Acid-Induced Steatosis in HepG2 Hepatocytes. Int J Mol Sci 2015;16:27749-56. [PMID: 26610473 DOI: 10.3390/ijms161126058] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
208 Li M, Shen Z, Li YM. Potential role of Helicobacter pylori infection in nonalcoholic fatty liver disease. World J Gastroenterol 2013; 19(41): 7024-7031 [PMID: 24222944 DOI: 10.3748/wjg.v19.i41.7024] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
209 Mu Y, She R, Zhang H, Dong B, Huang C, Lin W, Li D, Li X. Effects of estrogen and androgen deprivation on the progression of non-alcoholic steatohepatitis (NASH) in male Sprague-Dawley rats. Hepatol Res 2009;39:910-20. [PMID: 19453544 DOI: 10.1111/j.1872-034X.2009.00512.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
210 Edmunds LR, Xie B, Mills AM, Huckestein BR, Undamatla R, Murali A, Pangburn MM, Martin J, Sipula I, Kaufman BA, Scott I, Jurczak MJ. Liver-specific Prkn knockout mice are more susceptible to diet-induced hepatic steatosis and insulin resistance. Mol Metab 2020;41:101051. [PMID: 32653576 DOI: 10.1016/j.molmet.2020.101051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
211 van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr 2018;18:89-101. [PMID: 29212576 DOI: 10.3727/105221617X15124844266408] [Cited by in Crossref: 79] [Cited by in F6Publishing: 46] [Article Influence: 15.8] [Reference Citation Analysis]
212 Haidari F, Hojhabrimanesh A, Helli B, Seyedian SS, Ahmadi-Angali K. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial. Trials 2018;19:634. [PMID: 30445988 DOI: 10.1186/s13063-018-3014-8] [Reference Citation Analysis]
213 Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006;40:930-935. [PMID: 17063114 DOI: 10.1097/01.mcg.0000212608.59090.08] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 6.3] [Reference Citation Analysis]
214 Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22 Suppl 1:S20-S27. [PMID: 17567459 DOI: 10.1111/j.1440-1746.2006.04640.x] [Cited by in Crossref: 178] [Cited by in F6Publishing: 180] [Article Influence: 11.9] [Reference Citation Analysis]
215 Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. [DOI: 10.1053/gast.2002.34168] [Cited by in Crossref: 998] [Cited by in F6Publishing: 934] [Article Influence: 49.9] [Reference Citation Analysis]
216 Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM. 2003;96:699-709. [PMID: 14500857 DOI: 10.1093/qjmed/hcg120] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
217 Akazawa Y, Cazanave S, Mott JL, Elmi N, Bronk SF, Kohno S, Charlton MR, Gores GJ. Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis. J Hepatol. 2010;52:586-593. [PMID: 20206402 DOI: 10.1016/j.jhep.2010.01.003] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 12.6] [Reference Citation Analysis]
218 Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep 2003;5:364-71. [PMID: 12911846 DOI: 10.1007/s11883-003-0007-0] [Cited by in Crossref: 89] [Cited by in F6Publishing: 69] [Article Influence: 4.7] [Reference Citation Analysis]
219 Li Y, Wang J, Tang Y, Han X, Liu B, Hu H, Li X, Yang K, Yuan J, Miao X, Yao P, Wei S, Wang Y, Liang Y, Zhang X, Guo H, Pan A, Yang H, Hu FB, Wu T, He M. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study. PLoS One 2017;12:e0174291. [PMID: 28350839 DOI: 10.1371/journal.pone.0174291] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
220 Chiang DJ, Pritchard MT, Nagy LE. Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2011;300:G697-G702. [PMID: 21350183 DOI: 10.1152/ajpgi.00426.2010] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 9.6] [Reference Citation Analysis]
221 Utzschneider KM, Kahn SE. The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism 2006;91:4753-61. [DOI: 10.1210/jc.2006-0587] [Cited by in Crossref: 476] [Cited by in F6Publishing: 451] [Article Influence: 29.8] [Reference Citation Analysis]
222 Malaguarnera L, Madeddu R, Palio E, Arena N, Malaguarnera M. Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. J Hepatol 2005;42:585-91. [PMID: 15763346 DOI: 10.1016/j.jhep.2004.11.040] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 5.9] [Reference Citation Analysis]
223 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 742] [Article Influence: 194.3] [Reference Citation Analysis]
224 Terada R, Yamamoto K, Kobayashi K, Sakaguchi K, Iwasaki Y, Saheki T, Shiratori Y. Adult-onset type II citrullinemia associated with idopathic hypertriglyceridemia as a preceding feature. J Gastroenterol Hepatol 2006;21:1634-5. [DOI: 10.1111/j.1440-1746.2006.04339.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
225 Sumida Y, Yonei Y, Tanaka S, Mori K, Kanemasa K, Imai S, Taketani H, Hara T, Seko Y, Ishiba H, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Minami M, Itoh Y. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease: IGF-1 in advanced NASH. Hepatol Res 2015;45:771-81. [DOI: 10.1111/hepr.12408] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
226 Galloway CA, Yoon Y. Mitochondrial morphology in metabolic diseases. Antioxid Redox Signal. 2013;19:415-430. [PMID: 22793999 DOI: 10.1089/ars.2012.4779] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 6.9] [Reference Citation Analysis]
227 Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr. 2011;158:740-744. [PMID: 21168155 DOI: 10.1016/j.jpeds.2010.11.016] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 5.0] [Reference Citation Analysis]
228 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708. [PMID: 20955971 DOI: 10.1016/j.bpg.2010.08.005] [Cited by in Crossref: 128] [Cited by in F6Publishing: 115] [Article Influence: 11.6] [Reference Citation Analysis]
229 Serfaty L, Capeau J. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int. 2009;29 Suppl 2:13-25. [PMID: 19187069 DOI: 10.1111/j.1478-3231.2008.01952.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 4.7] [Reference Citation Analysis]
230 Min AK, Kim MK, Kim HS, Seo HY, Lee KU, Kim JG, Park KG, Lee IK. Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. Life Sci. 2012;90:200-205. [PMID: 22154902 DOI: 10.1016/j.lfs.2011.11.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
231 Passos E, Ascensão A, Martins MJ, Magalhães J. Endoplasmic Reticulum Stress Response in Non-alcoholic Steatohepatitis: The Possible Role of Physical Exercise. Metabolism 2015;64:780-92. [DOI: 10.1016/j.metabol.2015.02.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
232 Liangpunsakul S, Chalasani N. Treatment of Nonalcoholic Fatty Liver Disease. Curr Treat Option Gastroenterol. 2003;6:455-463. [PMID: 1458234 DOI: 10.1007/s11938-003-0047-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
233 Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66:180-190. [PMID: 27646933 DOI: 10.1136/gutjnl-2016-312431] [Cited by in Crossref: 214] [Cited by in F6Publishing: 213] [Article Influence: 35.7] [Reference Citation Analysis]
234 Adams LA, Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006;82:315-22. [PMID: 16679470 DOI: 10.1136/pgmj.2005.042200] [Cited by in Crossref: 165] [Cited by in F6Publishing: 148] [Article Influence: 10.3] [Reference Citation Analysis]
235 Videla LA, Pettinelli P. Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity. PPAR Res. 2012;2012:107434. [PMID: 23304111 DOI: 10.1155/2012/107434] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
236 Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952-964. [PMID: 22173168 DOI: 10.1016/j.jhep.2011.08.025] [Cited by in Crossref: 452] [Cited by in F6Publishing: 440] [Article Influence: 41.1] [Reference Citation Analysis]
237 Xia J, Zheng M, Li L, Hou X, Zeng W. [Conjugated linoleic acid improves glucose and lipid metabolism in diabetic mice]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:740-6. [PMID: 31270056 DOI: 10.12122/j.issn.1673-4254.2019.06.18] [Reference Citation Analysis]
238 Liu B, Xue J, Zhang M, Wang M, Ma T, Zhao M, Gu Q, Qin S. Hydrogen inhalation alleviates nonalcoholic fatty liver disease in metabolic syndrome rats. Mol Med Rep 2020;22:2860-8. [PMID: 32945408 DOI: 10.3892/mmr.2020.11364] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
239 Green RM. NASH--hepatic metabolism and not simply the metabolic syndrome. Hepatology. 2003;38:14-17. [PMID: 12829980 DOI: 10.1053/jhep.2003.50325] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 2.9] [Reference Citation Analysis]
240 Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology. 2002;35:497-499. [PMID: 11826428 DOI: 10.1053/jhep.2002.31551] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 4.7] [Reference Citation Analysis]
241 Kim HY, Park SY, Lee MH, Rho JH, Oh YJ, Jung HU, Yoo SH, Jeong NY, Lee HJ, Suh S, Seo SY, Cheong J, Jeong JS, Yoo YH. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance. Journal of Hepatology 2015;63:477-85. [DOI: 10.1016/j.jhep.2015.01.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
242 Yan Z, Zhang S, Tan C, Qin H, Belaroussi B, Yu HJ, Miller C, Metaxas DN. Atlas-based liver segmentation and hepatic fat-fraction assessment for clinical trials. Computerized Medical Imaging and Graphics 2015;41:80-92. [DOI: 10.1016/j.compmedimag.2014.05.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
243 Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90. [PMID: 15842582 DOI: 10.1111/j.1572-0241.2005.41583.x] [Cited by in Crossref: 473] [Cited by in F6Publishing: 413] [Article Influence: 27.8] [Reference Citation Analysis]
244 Sanyal AJ. Novel therapeutic targets for steatohepatitis. Clinics and Research in Hepatology and Gastroenterology 2015;39:S46-50. [DOI: 10.1016/j.clinre.2015.05.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
245 Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, Smit JW, Meinders AE, Jazet IM. Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol. 2012;2012:983814. [PMID: 22675355 DOI: 10.1155/2012/983814] [Cited by in Crossref: 134] [Cited by in F6Publishing: 124] [Article Influence: 13.4] [Reference Citation Analysis]
246 Larrieta-Carrasco E, Flores YN, Macías-Kauffer LR, Ramírez-Palacios P, Quiterio M, Ramírez-Salazar EG, León-Mimila P, Rivera-Paredez B, Cabrera-Álvarez G, Canizales-Quinteros S, Zhang ZF, López-Pérez TV, Salmerón J, Velázquez-Cruz R. Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population. Exp Mol Pathol 2018;104:50-8. [PMID: 29307798 DOI: 10.1016/j.yexmp.2018.01.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
247 Liu K, Czaja MJ. Regulation of lipid stores and metabolism by lipophagy. Cell Death Differ. 2013;20:3-11. [PMID: 22595754 DOI: 10.1038/cdd.2012.63] [Cited by in Crossref: 291] [Cited by in F6Publishing: 273] [Article Influence: 29.1] [Reference Citation Analysis]
248 Grant LM, Lisker-melman M. Nonalcoholic fatty liver disease. Annals of Hepatology 2004;3:93-9. [DOI: 10.1016/s1665-2681(19)32100-3] [Cited by in Crossref: 26] [Article Influence: 1.4] [Reference Citation Analysis]
249 Adams LA, Angulo P. Treatment of nonalcoholic steatohepatitis: antioxidants or insulin sensitizers. Clin Gastroenterol Hepatol. 2004;2:1059-1060. [PMID: 15625648 DOI: 10.1016/s1542-3565(04)00462-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
250 Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, Simard S, Marceau P. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004;135:48-58. [PMID: 14694300 DOI: 10.1016/j.surg.2003.10.003] [Cited by in Crossref: 222] [Cited by in F6Publishing: 193] [Article Influence: 12.3] [Reference Citation Analysis]
251 Wang G, Wu B, Zhang L, Jin X, Wang K, Xu W, Zhang B, Wang H. The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice. J Biochem Mol Toxicol 2021;35:e22696. [PMID: 33421258 DOI: 10.1002/jbt.22696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Méndez-Sánchez N, Chávez-Tapia NC, Villa AR, Sánchez-Lara K, Zamora-Valdés D, Ramos MH, Uribe M. Adiponectin as a protective factor in hepatic steatosis. World J Gastroenterol 2005; 11(12): 1737-1741 [PMID: 15793855 DOI: 10.3748/wjg.v11.i12.1737] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
253 Begriche K, Lettéron P, Abbey-Toby A, Vadrot N, Robin MA, Bado A, Pessayre D, Fromenty B. Partial leptin deficiency favors diet-induced obesity and related metabolic disorders in mice. Am J Physiol Endocrinol Metab. 2008;294:E939-E951. [PMID: 18349116 DOI: 10.1152/ajpendo.00379.2007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
254 Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH, Gores GJ. Mcl-1 degradation during hepatocyte lipoapoptosis. J Biol Chem 2009;284:30039-48. [PMID: 19734538 DOI: 10.1074/jbc.M109.039545] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
255 Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. J Biol Chem. 2011;286:39336-39348. [PMID: 21941003 DOI: 10.1074/jbc.m111.280420] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
256 Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72-82. [PMID: 15920328 DOI: 10.1159/000084728] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
257 Reaven GM. Compensatory Hyperinsulinemia and the Development of an Atherogenic Lipoprotein Profile: The Price Paid to Maintain Glucose Homeostasis in Insulin-Resistant Individuals. Endocrinology and Metabolism Clinics of North America 2005;34:49-62. [DOI: 10.1016/j.ecl.2004.12.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
258 Liu P, Lin H, Xu Y, Zhou F, Wang J, Liu J, Zhu X, Guo X, Tang Y, Yao P. Frataxin-Mediated PINK1-Parkin-Dependent Mitophagy in Hepatic Steatosis: The Protective Effects of Quercetin. Mol Nutr Food Res 2018;62:e1800164. [PMID: 29935106 DOI: 10.1002/mnfr.201800164] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 8.5] [Reference Citation Analysis]
259 Verdi H, Sare Koytak E, Önder O, Arslan Ergül A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu Ö, Bozkaya H. Peroxisome Proliferator-Activated Receptor α L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis: . Journal of Investigative Medicine 2005;53:353-9. [DOI: 10.2310/6650.2005.53706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
260 Gunn PJ, Pramfalk C, Millar V, Cornfield T, Hutchinson M, Johnson EM, Nagarajan SR, Troncoso-Rey P, Mithen RF, Pinnick KE, Traka MH, Green CJ, Hodson L. Modifying nutritional substrates induces macrovesicular lipid droplet accumulation and metabolic alterations in a cellular model of hepatic steatosis. Physiol Rep 2020;8:e14482. [PMID: 32643289 DOI: 10.14814/phy2.14482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
261 Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, Erbel R, Blankstein R, Feldman T, Al-Mallah MH, Santos RD, Budoff MJ, Nasir K. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 2013;230:258-267. [PMID: 24075754 DOI: 10.1016/j.atherosclerosis.2013.07.052] [Cited by in Crossref: 190] [Cited by in F6Publishing: 188] [Article Influence: 21.1] [Reference Citation Analysis]
262 Wang HN, Chen HD, Chen KY, Xiao JF, He K, Xiang GA, Xie X. Highly expressed MT-ND3 positively associated with histological severity of hepatic steatosis. APMIS. 2014;122:443-451. [PMID: 24020820 DOI: 10.1111/apm.12166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
263 Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 2012;47:215-225. [PMID: 22310735 DOI: 10.1007/s00535-012-0527-x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 9.9] [Reference Citation Analysis]
264 Hong ES, Kim EK, Kang SM, Khang AR, Choi SH, Park KS, Jang HC, Lim S. Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study. J Gastroenterol Hepatol. 2014;29:1449-1457. [PMID: 24611967 DOI: 10.1111/jgh.12536] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
265 Neuschwander-Tetri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci. 2005;330:326-335. [PMID: 16355018 DOI: 10.1097/00000441-200512000-00011] [Cited by in Crossref: 128] [Cited by in F6Publishing: 125] [Article Influence: 8.0] [Reference Citation Analysis]
266 Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8:25-30. [PMID: 18366995 DOI: 10.1007/s11892-008-0006-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
267 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578-584. [PMID: 15030972 DOI: 10.1016/j.jhep.2004.02.013] [Cited by in Crossref: 187] [Cited by in F6Publishing: 161] [Article Influence: 10.4] [Reference Citation Analysis]
268 Einhorn D. American College of Endocrinology Position Statement on the Insulin Resistance Syndrome. Endocrine Practice 2003;9:5-21. [DOI: 10.4158/ep.9.s2.5] [Cited by in Crossref: 141] [Article Influence: 7.4] [Reference Citation Analysis]
269 Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2002;16:709-731. [PMID: 12406441 DOI: 10.1053/bega.2002.0325] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 4.9] [Reference Citation Analysis]
270 Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS. 2002;16:2183-2193. [PMID: 12409740 DOI: 10.1097/00002030-200211080-00011] [Cited by in Crossref: 127] [Cited by in F6Publishing: 109] [Article Influence: 6.7] [Reference Citation Analysis]
271 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
272 Männistö VT, Simonen M, Hyysalo J, Soininen P, Kangas AJ, Kaminska D, Matte AK, Venesmaa S, Käkelä P, Kärjä V, Arola J, Gylling H, Cederberg H, Kuusisto J, Laakso M, Yki-järvinen H, Ala-korpela M, Pihlajamäki J. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int 2015;35:1853-61. [DOI: 10.1111/liv.12769] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
273 Grattagliano I, de Bari O, Bernardo TC, Oliveira PJ, Wang DQ, Portincasa P. Role of mitochondria in nonalcoholic fatty liver disease--from origin to propagation. Clin Biochem. 2012;45:610-618. [PMID: 22484459 DOI: 10.1016/j.clinbiochem.2012.03.024] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 7.9] [Reference Citation Analysis]
274 Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, Chiu CC, Chuang WL, Tsai TR, Yu ML. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22:2118-2123. [PMID: 18031368 DOI: 10.1111/j.1440-1746.2006.04698.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis]
275 Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat. 2004;11:91-96. [PMID: 14738564 DOI: 10.1046/j.1365-2893.2003.00483.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 3.1] [Reference Citation Analysis]
276 Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774-788. [PMID: 20683968 DOI: 10.1002/hep.23719] [Cited by in Crossref: 606] [Cited by in F6Publishing: 583] [Article Influence: 50.5] [Reference Citation Analysis]
277 Comar KM, Sterling RK. Review article: Drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;23:207-215. [PMID: 16393299 DOI: 10.1111/j.1365-2036.2006.02751.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
278 Arumugam MK, Paal MC, Donohue TM Jr, Ganesan M, Osna NA, Kharbanda KK. Beneficial Effects of Betaine: A Comprehensive Review. Biology (Basel) 2021;10:456. [PMID: 34067313 DOI: 10.3390/biology10060456] [Reference Citation Analysis]
279 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
280 Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, Tokusashi Y, Miyokawa N, Nakamura K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222-1225. [PMID: 15382153 DOI: 10.1002/hep.20420] [Cited by in Crossref: 336] [Cited by in F6Publishing: 299] [Article Influence: 18.7] [Reference Citation Analysis]
281 Yu Q, Tan S, Ren Y, He M, Fu X, Peng Y, Tang X. Bibliometric analysis of the 100 most-cited articles in the field of hepatology. Gastroenterol Hepatol 2020;43:349-57. [PMID: 32241600 DOI: 10.1016/j.gastrohep.2019.11.015] [Reference Citation Analysis]
282 Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial: METFORMIN IN NASH. Alimentary Pharmacology & Therapeutics 2004;20:23-8. [DOI: 10.1111/j.1365-2036.2004.02025.x] [Cited by in Crossref: 254] [Cited by in F6Publishing: 226] [Article Influence: 14.1] [Reference Citation Analysis]
283 Kim M, Yang SG, Kim JM, Lee JW, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells. Int J Mol Med. 2012;30:473-479. [PMID: 22710359 DOI: 10.3892/ijmm.2012.1029] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
284 Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, He H, Liu X, Li Y, Yu C. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925-932. [PMID: 26639394 DOI: 10.1016/j.jhep.2015.11.022] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
285 Gao Y, Song LX, Jiang MN, Ge GY, Jia YJ. Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation. 2008;31:121-132. [PMID: 18302012 DOI: 10.1007/s10753-008-9057-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
286 Mazzone G, Morisco C, Lembo V, D'Argenio G, D'Armiento M, Rossi A, Giudice CD, Trimarco B, Caporaso N, Morisco F. Dietary supplementation of vitamin D prevents the development of western diet-induced metabolic, hepatic and cardiovascular abnormalities in rats.United European Gastroenterol J. 2018;6:1056-1064. [PMID: 30228894 DOI: 10.1177/2050640618774140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
287 Zhang Q, Lou Y, Bai XL, Liang TB. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol 2018; 24(31): 3500-3512 [PMID: 30131656 DOI: 10.3748/wjg.v24.i31.3500] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
288 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
289 Choi Y, Abdelmegeed MA, Song BJ. Preventive effects of dietary walnuts on high-fat-induced hepatic fat accumulation, oxidative stress and apoptosis in mice. J Nutr Biochem 2016;38:70-80. [PMID: 27732911 DOI: 10.1016/j.jnutbio.2016.08.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
290 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 329] [Cited by in F6Publishing: 309] [Article Influence: 54.8] [Reference Citation Analysis]
291 Yunianingtias D, Volker D. Nutritional aspects of non-alcoholic steatohepatitis treatment. Nutrition & Dietetics 2006;63:79-90. [DOI: 10.1111/j.1747-0080.2006.00054.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
292 Liu M, Xu L, Yin L, Qi Y, Xu Y, Han X, Zhao Y, Sun H, Yao J, Lin Y. Potent effects of dioscin against obesity in mice. Sci Rep. 2015;5:7973. [PMID: 25609476 DOI: 10.1038/srep07973] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
293 Marina A, von Frankenberg AD, Suvag S, Callahan HS, Kratz M, Richards TL, Utzschneider KM. Effects of dietary fat and saturated fat content on liver fat and markers of oxidative stress in overweight/obese men and women under weight-stable conditions. Nutrients. 2014;6:4678-4690. [PMID: 25353663 DOI: 10.3390/nu6114678] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
294 Igolnikov AC, Green RM. Mice heterozygous for the Mdr2 gene demonstrate decreased PEMT activity and diminished steatohepatitis on the MCD diet. J Hepatol 2006;44:586-92. [PMID: 16376450 DOI: 10.1016/j.jhep.2005.08.026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
295 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016; 22(32): 7236-7251 [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 98] [Article Influence: 17.7] [Reference Citation Analysis]
296 Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology. 2008;48:770-781. [PMID: 18752326 DOI: 10.1002/hep.22423] [Cited by in Crossref: 163] [Cited by in F6Publishing: 149] [Article Influence: 11.6] [Reference Citation Analysis]
297 Yoneda M, Endo H, Mawatari H, Nozaki Y, Fujita K, Akiyama T, Higurashi T, Uchiyama T, Yoneda K, Takahashi H. Gene expression profiling of non-alcoholic steatohepatitis using gene set enrichment analysis. Hepatol Res. 2008;38:1204-1212. [PMID: 18637145 DOI: 10.1111/j.1872-034x.2008.00399.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
298 Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol. 2002;9:37-51. [PMID: 11756758 DOI: 10.1097/00125480-200201000-00005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
299 Moreno Sánchez D. [Pathogenesis of primary nonalcoholic fatty liver disease]. Med Clin (Barc) 2005;124:668-77. [PMID: 15882516 DOI: 10.1157/13074744] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
300 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 482] [Article Influence: 30.4] [Reference Citation Analysis]
301 Bergasa NV, Mehlman J, Bir K. Aerobic exercise: a potential therapeutic intervention for patients with liver disease. Medical Hypotheses 2004;62:935-41. [DOI: 10.1016/j.mehy.2003.12.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
302 Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;152:116-41. [PMID: 32156524 DOI: 10.1016/j.freeradbiomed.2020.02.025] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 45.0] [Reference Citation Analysis]
303 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Tuleta I, Frangogiannis NG. Diabetic fibrosis. Biochim Biophys Acta Mol Basis Dis 2021;1867:166044. [PMID: 33378699 DOI: 10.1016/j.bbadis.2020.166044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
305 Serviddio G, Bellanti F, Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med. 2013;65:952-968. [PMID: 23994574 DOI: 10.1016/j.freeradbiomed.2013.08.174] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 14.8] [Reference Citation Analysis]
306 Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS. 2005;19:356-365. [PMID: 15989431 DOI: 10.1089/apc.2005.19.356] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
307 Duvnjak M, Lerotić I, Baršić N, Tomašić V, Jukić LV, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13(34): 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539] [Cited by in CrossRef: 157] [Cited by in F6Publishing: 142] [Article Influence: 10.5] [Reference Citation Analysis]
308 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 13.4] [Reference Citation Analysis]
309 Schierwagen R, Maybüchen L, Zimmer S, Hittatiya K, Bäck C, Klein S, Uschner FE, Reul W, Boor P, Nickenig G, Strassburg CP, Trautwein C, Plat J, Lütjohann D, Sauerbruch T, Tacke F, Trebicka J. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep 2015;5:12931. [PMID: 26263022 DOI: 10.1038/srep12931] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 11.9] [Reference Citation Analysis]
310 Bramlage KS, Bhattacharjee J, Kirby M, Myronovych A, Gupta R, Gonzalez RS, Xanthakos S, Bove K, Kohli R. A Diet High in Fat and Fructose Induces Early Hepatic Mitochondrial Aging. J Pediatr Gastroenterol Nutr 2021;73:99-102. [PMID: 34135298 DOI: 10.1097/MPG.0000000000003068] [Reference Citation Analysis]
311 Law K, Brunt EM. Nonalcoholic fatty liver disease. Clin Liver Dis. 2010;14:591-604. [PMID: 21055684 DOI: 10.1016/j.cld.2010.07.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
312 Fuchs M. New Medical Treatment Strategies for Nonalcoholic Steatohepatitis. Curr Treat Options Gastro 2015;13:259-73. [DOI: 10.1007/s11938-015-0053-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
313 Neuschwander-Tetri BA. NASH: Thiazolidinediones for NASH--one pill doesn’t fix everything. Nat Rev Gastroenterol Hepatol. 2010;7:243-244. [PMID: 20442730 DOI: 10.1038/nrgastro.2010.50] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
314 Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17 Suppl:S186-S190. [PMID: 12000605 DOI: 10.1046/j.1440-1746.17.s1.10.x] [Cited by in Crossref: 283] [Cited by in F6Publishing: 266] [Article Influence: 14.2] [Reference Citation Analysis]
315 Darcy J, Bartke A. From White to Brown - Adipose Tissue Is Critical to the Extended Lifespan and Healthspan of Growth Hormone Mutant Mice. Adv Exp Med Biol 2019;1178:207-25. [PMID: 31493229 DOI: 10.1007/978-3-030-25650-0_11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
316 Tiniakos DG. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. Gastroenterol Clin Biol. 2009;33:930-939. [PMID: 19646834 DOI: 10.1016/j.gcb.2009.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
317 Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36-44. [PMID: 27757953 DOI: 10.1002/path.4829] [Cited by in Crossref: 162] [Cited by in F6Publishing: 153] [Article Influence: 27.0] [Reference Citation Analysis]
318 Khammas ASA, Hassan HA, Salih SQM, Kadir H, Ibrahim RM, Nasir NNM, Mahmud R. Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study. Porto Biomed J 2019;4:e31. [PMID: 31595260 DOI: 10.1016/j.pbj.0000000000000031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
319 Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A, Zavaroni I, Marchesini G. Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. J Endocrinol Invest 2008;31:146-52. [DOI: 10.1007/bf03345581] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
320 Mendes FD, Lindor KD. Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opinion on Investigational Drugs 2005;14:29-35. [DOI: 10.1517/13543784.14.1.29] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
321 Cazanave SC, Sanyal AJ. Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease. In: Ntambi JM, editor. Hepatic De Novo Lipogenesis and Regulation of Metabolism. Cham: Springer International Publishing; 2016. pp. 101-29. [DOI: 10.1007/978-3-319-25065-6_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
322 García-Ruiz I, Solís-Muñoz P, Fernández-Moreira D, Muñoz-Yagüe T, Solís-Herruzo JA. In vitro treatment of HepG2 cells with saturated fatty acids reproduces mitochondrial dysfunction found in nonalcoholic steatohepatitis. Dis Model Mech 2015;8:183-91. [PMID: 25540128 DOI: 10.1242/dmm.018234] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
323 Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology. 2005;42:987-1000. [PMID: 16250043 DOI: 10.1002/hep.20920] [Cited by in Crossref: 512] [Cited by in F6Publishing: 465] [Article Influence: 30.1] [Reference Citation Analysis]
324 Szendroedi J, Roden M. Mitochondrial fitness and insulin sensitivity in humans. Diabetologia 2008;51:2155-67. [PMID: 18802678 DOI: 10.1007/s00125-008-1153-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
325 Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Front Pharmacol 2020;11:603926. [PMID: 33343375 DOI: 10.3389/fphar.2020.603926] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
326 Aygun C, Senturk O, Hulagu S, Uraz S, Celebi A, Konduk T, Mutlu B, Canturk Z. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2006;18:175-180. [PMID: 16394799 DOI: 10.1097/00042737-200602000-00010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
327 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
328 Mazi TA, Borkowski K, Newman JW, Fiehn O, Bowlus CL, Sarkar S, Matsukuma K, Ali MR, Kieffer DA, Wan YY, Stanhope KL, Havel PJ, Medici V. Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study. Free Radic Biol Med 2021;172:490-502. [PMID: 34182070 DOI: 10.1016/j.freeradbiomed.2021.06.024] [Reference Citation Analysis]
329 Song S. The role of increased liver triglyceride content: a culprit of diabetic hyperglycaemia? Diabetes Metab Res Rev 2002;18:5-12. [PMID: 11921413 DOI: 10.1002/dmrr.260] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
330 Heeks LV, Hooper AJ, Adams LA, Robbins P, Barrett PHR, van Bockxmeer FM, Burnett JR. Non-alcoholic steatohepatitis-related cirrhosis in a patient with APOB L343V familial hypobetalipoproteinaemia. Clinica Chimica Acta 2013;421:121-5. [DOI: 10.1016/j.cca.2013.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
331 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
332 Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015;11:137-141. [PMID: 25701959 DOI: 10.1016/j.soard.2014.06.015] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
333 Rinella ME, Siddiqui MS, Gardikiotes K, Gottstein J, Elias M, Green RM. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology 2011;54:1600-9. [PMID: 21748768 DOI: 10.1002/hep.24553] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.2] [Reference Citation Analysis]
334 Zhao M, Chen S, Ji X, Shen X, You J, Liang X, Yin H, Zhao L. Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. Pharmacol Res 2021;166:105517. [PMID: 33636349 DOI: 10.1016/j.phrs.2021.105517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Yang HY, Tzeng YH, Chai CY, Hsieh AT, Chen JR, Chang LS, Yang SS. Soy protein retards the progression of non-alcoholic steatohepatitis via improvement of insulin resistance and steatosis. Nutrition. 2011;27:943-948. [PMID: 21333494 DOI: 10.1016/j.nut.2010.09.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
336 Hoteit MA, Anania FA. Treatment of fibrosis in nonalcoholic fatty liver disease. Curr Gastroenterol Rep 2007;9:47-53. [PMID: 17335677 DOI: 10.1007/s11894-008-0020-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
337 Assy N, Nassar F, Nasser G, Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol 2009; 15(15): 1809-1815 [PMID: 19370776 DOI: 10.3748/wjg.15.1809] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 84] [Article Influence: 6.8] [Reference Citation Analysis]
338 Ye FZ, Liu WY, Zheng KI, Pan XY, Ma HL, Wang XD, Chen YP, Zheng MH. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2020;32:80-6. [PMID: 31625959 DOI: 10.1097/MEG.0000000000001483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
339 Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18:588-594. [PMID: 12702052 DOI: 10.1046/j.1440-1746.2003.02958.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 6.3] [Reference Citation Analysis]
340 Pessayre D, Mansouri A, Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2002;282:G193-9. [PMID: 11804839 DOI: 10.1152/ajpgi.00426.2001] [Cited by in Crossref: 160] [Cited by in F6Publishing: 158] [Article Influence: 8.0] [Reference Citation Analysis]
341 Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854-8. [PMID: 15242486 DOI: 10.1111/j.1440-1746.2004.03312.x] [Cited by in Crossref: 184] [Cited by in F6Publishing: 168] [Article Influence: 10.8] [Reference Citation Analysis]
342 Campos ML, Castro MB, Campos AD, Fernandes MF, Conegundes JLM, Rodrigues MN, Mügge FLB, Silva AMD, Sabarense CM, Castañon MCMN, Andreazzi AE, Scio E. Antiobesity, hepatoprotective and anti-hyperglycemic effects of a pharmaceutical formulation containing Cecropia pachystachya Trécul in mice fed with a hypercaloric diet. J Ethnopharmacol 2021;280:114418. [PMID: 34271111 DOI: 10.1016/j.jep.2021.114418] [Reference Citation Analysis]
343 Dey A, Swaminathan K. Hyperglycemia-induced mitochondrial alterations in liver. Life Sciences 2010;87:197-214. [DOI: 10.1016/j.lfs.2010.06.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
344 Kwak DH, Kim JS, Chang KT, Choo YK. Aristolochia manshuriensis Kom ethyl acetate extract protects against high-fat diet-induced non-alcoholic steatohepatitis by regulating kinase phosphorylation in mouse. J Vet Sci 2016;17:279-87. [PMID: 26726030 DOI: 10.4142/jvs.2016.17.3.279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
345 Kumemura H, Harada M, Yanagimoto C, Koga H, Kawaguchi T, Hanada S, Taniguchi E, Ueno T, Sata M. Mutation in keratin 18 induces mitochondrial fragmentation in liver-derived epithelial cells. Biochemical and Biophysical Research Communications 2008;367:33-40. [DOI: 10.1016/j.bbrc.2007.12.116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
346 García-Roche M, Casal A, Mattiauda DA, Ceriani M, Jasinsky A, Mastrogiovanni M, Trostchansky A, Carriquiry M, Cassina A, Quijano C. Impaired hepatic mitochondrial function during early lactation in dairy cows: Association with protein lysine acetylation. PLoS One 2019;14:e0213780. [PMID: 30870481 DOI: 10.1371/journal.pone.0213780] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
347 Filippatos TD, Elisaf MS. Role of ezetimibe in non-alcoholic fatty liver disease. World J Hepatology 2011; 3(10): 265-267 [PMID: 22059109 DOI: 10.4254/wjh.v3.i10.265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
348 Huang HH, Chen YL, Chen JS, Lin JD, Hsieh CH, Pei D, Wu CZ. Relationships Among C-Reactive Protein, Alanine Aminotransferase, and Metabolic Syndrome in Apparently Healthy Chinese Subjects. Metab Syndr Relat Disord 2018;16:232-9. [PMID: 29688806 DOI: 10.1089/met.2017.0059] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
349 Gonzalez Rozas M, Hernanz Roman L, Gonzalez DG, Pérez-Castrillón JL. Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis. Case Rep Endocrinol 2016;2016:9071097. [PMID: 27213061 DOI: 10.1155/2016/9071097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
350 Hameed B, Terrault N. Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:365-85. [PMID: 27063275 DOI: 10.1016/j.cld.2015.10.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
351 Tomita K, Kohli R, MacLaurin BL, Hirsova P, Guo Q, Sanchez LHG, Gelbard HA, Blaxall BC, Ibrahim SH. Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis. JCI Insight 2017;2:94488. [PMID: 28768902 DOI: 10.1172/jci.insight.94488] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
352 Shi T, Yu L, Zhuang R, Xi J, He R, Shao Y, Huang J, Liu S, Yang X. Regulation of Mitochondrial Function by Natural Products for the Treatment of Metabolic Associated Fatty Liver Disease. Can J Gastroenterol Hepatol 2021;2021:5527315. [PMID: 34222135 DOI: 10.1155/2021/5527315] [Reference Citation Analysis]
353 Ure DR, Trepanier DJ, Mayo PR, Foster RT. Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH). Expert Opinion on Investigational Drugs 2020;29:163-78. [DOI: 10.1080/13543784.2020.1703948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
354 Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D. 2015;15:21-25. [PMID: 25732561 DOI: 10.1007/s40268-015-0084-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
355 Li Q, Huang Y. Mitochondrial targeted strategies and their application for cancer and other diseases treatment. J Pharm Investig 2020;50:271-93. [DOI: 10.1007/s40005-020-00481-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
356 Yan F, Zhang J, Zhang L, Zheng X. Mulberry anthocyanin extract regulates glucose metabolism by promotion of glycogen synthesis and reduction of gluconeogenesis in human HepG2 cells. Food Funct 2016;7:425-33. [PMID: 26467565 DOI: 10.1039/c5fo00841g] [Cited by in Crossref: 45] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
357 Tanaka H, Fukahori S, Baba S, Ueno T, Sivakumar R, Yagi M, Asagiri K, Ishii S, Tanaka Y. Branched-Chain Amino Acid-Rich Supplements Containing Microelements Have Antioxidant Effects on Nonalcoholic Steatohepatitis in Mice. JPEN J Parenter Enteral Nutr. 2016;40:519-528. [PMID: 25316683 DOI: 10.1177/0148607114555160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
358 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
359 Alisi A, Manco M, Panera N, Nobili V. Association between type two diabetes and non-alcoholic fatty liver disease in youth. Annals of Hepatology 2009;8:S44-50. [DOI: 10.1016/s1665-2681(19)31826-5] [Cited by in Crossref: 23] [Article Influence: 1.8] [Reference Citation Analysis]
360 Elemeery MN. Micro-RNA in Hepatocellular Carcinoma - Related Hepatitis C Virus Patients in Correlation to Disease Progression. In: Shahid I, editor. Hepatitis C - From Infection to Cure. InTech; 2018. [DOI: 10.5772/intechopen.76209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
361 Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology. 2006;43:163-172. [PMID: 16374858 DOI: 10.1002/hep.20999] [Cited by in Crossref: 289] [Cited by in F6Publishing: 284] [Article Influence: 18.1] [Reference Citation Analysis]
362 Stein LL, Dong MH, Loomba R. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Adv Ther 2009;26:893-907. [PMID: 19921118 DOI: 10.1007/s12325-009-0072-z] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
363 Thibaut R, Gage MC, Pineda-Torra I, Chabrier G, Venteclef N, Alzaid F. Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. FEBS J 2021. [PMID: 33860630 DOI: 10.1111/febs.15877] [Reference Citation Analysis]
364 Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500-505. [PMID: 14571229 DOI: 10.1067/s0022-3476(03)00325-1] [Cited by in Crossref: 327] [Cited by in F6Publishing: 114] [Article Influence: 17.2] [Reference Citation Analysis]
365 Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017;25:262-284. [PMID: 28178565 DOI: 10.1016/j.cmet.2016.12.022] [Cited by in Crossref: 430] [Cited by in F6Publishing: 397] [Article Influence: 86.0] [Reference Citation Analysis]
366 Mashek DG. Hepatic fatty acid trafficking: multiple forks in the road. Adv Nutr 2013;4:697-710. [PMID: 24228201 DOI: 10.3945/an.113.004648] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
367 Ibrahim SH, Gores GJ. Who pulls the trigger: JNK activation in liver lipotoxicity? J Hepatol. 2012;56:17-19. [PMID: 21703172 DOI: 10.1016/j.jhep.2011.04.017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
368 Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems: . European Journal of Gastroenterology & Hepatology 2010. [DOI: 10.1097/meg.0b013e32832ca0cb] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
369 Rodríguez-Antonio I, López-Sánchez GN, Garrido-Camacho VY, Uribe M, Chávez-Tapia NC, Nuño-Lámbarri N. Cholecystectomy as a risk factor for non-alcoholic fatty liver disease development. HPB (Oxford) 2020;22:1513-20. [PMID: 32773176 DOI: 10.1016/j.hpb.2020.07.011] [Reference Citation Analysis]
370 Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol 2007;102:1397-405. [PMID: 17488248 DOI: 10.1111/j.1572-0241.2007.01262.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
371 Sun WH, Song MQ, Jiang CQ, Xin YN, Ma JL, Liu YX, Ma L, Lin ZH, Li CY, Liu L, Zhang M, Chu LL, Jiang XJ, Wan Q, Zhou L, Ren R, Meng LF. Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China. World J Hepatol 2012; 4(7): 224-230 [PMID: 22855698 DOI: 10.4254/wjh.v4.i7.224] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
372 Loomba R, Kayali Z, Noureddin M, Ruane P, Lawitz EJ, Bennett M, Wang L, Harting E, Tarrant JM, McColgan BJ, Chung C, Ray AS, Subramanian GM, Myers RP, Middleton MS, Lai M, Charlton M, Harrison SA. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155:1463-1473.e6. [PMID: 30059671 DOI: 10.1053/j.gastro.2018.07.027] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 27.8] [Reference Citation Analysis]
373 Gellrich L, Merk D. Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Nuclear Receptor Research 2017;4. [DOI: 10.11131/2017/101310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
374 Gentric G, Maillet V, Paradis V, Couton D, L’Hermitte A, Panasyuk G, Fromenty B, Celton-Morizur S, Desdouets C. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest. 2015;125:981-992. [PMID: 25621497 DOI: 10.1172/jci73957] [Cited by in Crossref: 125] [Cited by in F6Publishing: 75] [Article Influence: 17.9] [Reference Citation Analysis]
375 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 27.4] [Reference Citation Analysis]
376 Pihlajamäki J, Kuulasmaa T, Kaminska D, Simonen M, Kärjä V, Grönlund S, Käkelä P, Pääkkönen M, Kainulainen S, Punnonen K. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol. 2012;56:663-670. [PMID: 22027586 DOI: 10.1016/j.jhep.2011.10.005] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 5.7] [Reference Citation Analysis]
377 Lei S, Sun RZ, Wang D, Gong MZ, Su XP, Yi F, Peng ZW. Increased Hepatic Fatty Acids Uptake and Oxidation by LRPPRC-Driven Oxidative Phosphorylation Reduces Blood Lipid Levels. Front Physiol 2016;7:270. [PMID: 27462273 DOI: 10.3389/fphys.2016.00270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
378 Zhou X, Han D, Xu R, Wu H, Qu C, Wang F, Wang X, Zhao Y. Glycine protects against high sucrose and high fat-induced non-alcoholic steatohepatitis in rats. Oncotarget 2016;7:80223-37. [PMID: 27784003 DOI: 10.18632/oncotarget.12831] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
379 Ariz U, Mato JM, Lu SC, Martínez Chantar ML. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? Methods Mol Biol. 2010;593:109-136. [PMID: 19957147 DOI: 10.1007/978-1-60327-194-3_6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
380 Le J, Jia W, Sun Y. Sennoside A protects mitochondrial structure and function to improve high-fat diet-induced hepatic steatosis by targeting VDAC1. Biochem Biophys Res Commun. 2018;500:484-489. [PMID: 29673597 DOI: 10.1016/j.bbrc.2018.04.108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
381 Lee J, Park J, Roh YS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res 2019;42:935-46. [DOI: 10.1007/s12272-019-01178-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
382 Kwon H, Song K, Han C, Chen W, Wang Y, Dash S, Lim K, Wu T. Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease. Hepatology. 2016;63:1155-1169. [PMID: 26473743 DOI: 10.1002/hep.28289] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
383 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
384 Sundaresan S, Vijayagopal P, Mills N, Imrhan V, Prasad C. A mouse model for nonalcoholic steatohepatitis. The Journal of Nutritional Biochemistry 2011;22:979-84. [DOI: 10.1016/j.jnutbio.2010.08.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
385 Lockman KA, Htun V, Sinha R, Treskes P, Nelson LJ, Martin SF, Rogers SM, Le Bihan T, Hayes PC, Plevris JN. Proteomic profiling of cellular steatosis with concomitant oxidative stress in vitro. Lipids Health Dis 2016;15:114. [PMID: 27368608 DOI: 10.1186/s12944-016-0283-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
386 Chella Krishnan K, Vergnes L, Acín-Pérez R, Stiles L, Shum M, Ma L, Mouisel E, Pan C, Moore TM, Péterfy M, Romanoski CE, Reue K, Björkegren JLM, Laakso M, Liesa M, Lusis AJ. Sex-specific genetic regulation of adipose mitochondria and metabolic syndrome by Ndufv2. Nat Metab 2021;3:1552-68. [PMID: 34697471 DOI: 10.1038/s42255-021-00481-w] [Reference Citation Analysis]
387 Caldwell SH, Chang CY, Nakamoto RK, Krugner-Higby L. Mitochondria in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:595-617, x. [PMID: 15331066 DOI: 10.1016/j.cld.2004.04.009] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 4.4] [Reference Citation Analysis]
388 Szendroedi J, Phielix E, Roden M. The role of mitochondria in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 2011;8:92-103. [PMID: 21912398 DOI: 10.1038/nrendo.2011.138] [Cited by in Crossref: 333] [Cited by in F6Publishing: 310] [Article Influence: 30.3] [Reference Citation Analysis]
389 Neuschwander-tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. Journal of Hepatology 2003;38:434-40. [DOI: 10.1016/s0168-8278(03)00027-8] [Cited by in Crossref: 88] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
390 Willy Haukeland J, Konopski Z, Linnestad P, Azimy S, Marit Løberg E, Haaland T, Birkeland K, Bjøro K. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2009;40:1469-77. [DOI: 10.1080/00365520500264953] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
391 Sumida Y, Yonei Y, Kanemasa K, Hara T, Inada Y, Sakai K, Imai S, Hibino S, Yamaguchi K, Mitsuyoshi H. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res. 2010;40:901-910. [PMID: 20887595 DOI: 10.1111/j.1872-034x.2010.00704.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
392 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 2018;75:3313-27. [PMID: 29936596 DOI: 10.1007/s00018-018-2860-6] [Cited by in Crossref: 234] [Cited by in F6Publishing: 231] [Article Influence: 58.5] [Reference Citation Analysis]
393 Di Pino A, DeFronzo RA. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocr Rev 2019;40:1447-67. [PMID: 31050706 DOI: 10.1210/er.2018-00141] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 25.5] [Reference Citation Analysis]
394 Ter Horst KW, Serlie MJ. Fructose Consumption, Lipogenesis, and Non-Alcoholic Fatty Liver Disease. Nutrients. 2017;9. [PMID: 28878197 DOI: 10.3390/nu9090981] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 15.8] [Reference Citation Analysis]
395 Edelman D, Kalia H, Delio M, Alani M, Krishnamurthy K, Abd M, Auton A, Wang T, Wolkoff AW, Morrow BE. Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population. Mol Genet Genomic Med 2015;3:558-69. [PMID: 26740948 DOI: 10.1002/mgg3.168] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
396 Östlund C, Hernandez-Ono A, Shin JY. The Nuclear Envelope in Lipid Metabolism and Pathogenesis of NAFLD. Biology (Basel) 2020;9:E338. [PMID: 33076344 DOI: 10.3390/biology9100338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
397 Tajiri K, Shimizu Y, Tsuneyama K, Sugiyama T. Role of liver-infiltrating CD3+CD56+ natural killer T cells in the pathogenesis of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2009;21:673-680. [PMID: 19318971 DOI: 10.1097/meg.0b013e32831bc3d6] [Cited by in Crossref: 72] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
398 Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, Considine RV. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol. 2003;98:2771-2776. [PMID: 14687831 DOI: 10.1111/j.1572-0241.2003.08767.x] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 5.7] [Reference Citation Analysis]
399 Leclercq IA, Lebrun VA, Stärkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone. Lab Invest. 2007;87:56-65. [PMID: 17075577 DOI: 10.1038/labinvest.3700489] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 4.8] [Reference Citation Analysis]
400 Pi-sunyer FX. Pathophysiology and Long-Term Management of the Metabolic Syndrome. Obesity Research 2004;12:174S-80S. [DOI: 10.1038/oby.2004.285] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
401 González-Rodríguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillón J, Lo Iacono O, Corazzari M, Fimia GM. Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis. 2014;5:e1179. [PMID: 24743734 DOI: 10.1038/cddis.2014.162] [Cited by in Crossref: 287] [Cited by in F6Publishing: 281] [Article Influence: 35.9] [Reference Citation Analysis]
402 Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013;97:326-331. [PMID: 23269818 DOI: 10.3945/ajcn.112.046417] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
403 Kohli R, Pan X, Malladi P, Wainwright MS, Whitington PF. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J Biol Chem 2007;282:21327-36. [PMID: 17540768 DOI: 10.1074/jbc.M701759200] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
404 Sevastianos VA, Voulgaris TA, Dourakis SP. Hepatitis C, systemic inflammation and oxidative stress: correlations with metabolic diseases. Expert Review of Gastroenterology & Hepatology 2020;14:27-37. [DOI: 10.1080/17474124.2020.1708191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
405 Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ;  Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54:753-759. [PMID: 21126792 DOI: 10.1016/j.jhep.2010.07.040] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 9.4] [Reference Citation Analysis]
406 Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res 2011;52:593-617. [PMID: 21245030 DOI: 10.1194/jlr.R008896] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
407 Maruyama H, Takahashi M, Sekimoto T, Shimada T, Yokosuka O. Linoleate appears to protect against palmitate-induced inflammation in Huh7 cells. Lipids Health Dis 2014;13:78. [PMID: 24885871 DOI: 10.1186/1476-511X-13-78] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
408 Desterke C, Chiappini F. Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway. Int J Mol Sci 2019;20:E5594. [PMID: 31717414 DOI: 10.3390/ijms20225594] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
409 García-ruiz C, Baulies A, Mari M, García-rovés PM, Fernandez-checa JC. Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: Cause or consequence? Free Radical Research 2013;47:854-68. [DOI: 10.3109/10715762.2013.830717] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 6.2] [Reference Citation Analysis]
410 Diao L, Auger C, Konoeda H, Sadri AR, Amini-Nik S, Jeschke MG. Hepatic steatosis associated with decreased β-oxidation and mitochondrial function contributes to cell damage in obese mice after thermal injury. Cell Death Dis 2018;9:530. [PMID: 29748608 DOI: 10.1038/s41419-018-0531-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
411 Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, Cusi K. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther. 2010;32:769-775. [PMID: 20662773 DOI: 10.1111/j.1365-2036.2010.04405.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.0] [Reference Citation Analysis]
412 Macias J, Rivero-Juarez A, Neukam K, Tellez F, Merino D, Frias M, Merchante N, Rivero A, Pineda JA, Real LM; HEPAVIR study group. Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. AIDS 2015;29:1927-35. [PMID: 26352879 DOI: 10.1097/QAD.0000000000000799] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
413 Mathurin P, Gonzalez F, Kerdraon O, Leteurtre E, Arnalsteen L, Hollebecque A, Louvet A, Dharancy S, Cocq P, Jany T, Boitard J, Deltenre P, Romon M, Pattou F. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology. 2006;130:1617-1624. [PMID: 16697725 DOI: 10.1053/j.gastro.2006.02.024] [Cited by in Crossref: 105] [Cited by in F6Publishing: 100] [Article Influence: 6.6] [Reference Citation Analysis]
414 Silva MA, Ataide Tda R, Oliveira SL, Sant'ana AE, Cabral Júnior CR, Balwani Mdo C, de Oliveira FG, Santos MC. [Hepatoprotective effect of diheptanoin and tritreptanoin chronic consumption against steatosis in rats]. Arq Bras Endocrinol Metabol 2008;52:1145-55. [PMID: 19082303 DOI: 10.1590/s0004-27302008000700011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
415 Takahashi Y, Fukusato T. Pediatric nonalcoholic fatty liver disease: Overview with emphasis on histology. World J Gastroenterol 2010; 16(42): 5280-5285 [PMID: 21072890 DOI: 10.3748/wjg.v16.i42.5280] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
416 Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, Sanyal AJ. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568-576. [PMID: 18082745 DOI: 10.1053/j.gastro.2007.10.039] [Cited by in Crossref: 383] [Cited by in F6Publishing: 356] [Article Influence: 25.5] [Reference Citation Analysis]
417 Chen J, Chen J, Fu H, Li Y, Wang L, Luo S, Lu H. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway. American Journal of Physiology-Endocrinology and Metabolism 2019;317:E710-22. [DOI: 10.1152/ajpendo.00052.2019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
418 Bilgin H, Pirgon Ö. Thyroid function in obese children with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2014;6:152-7. [PMID: 25241608 DOI: 10.4274/Jcrpe.1488] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
419 Mora SI, García-román J, Gómez-ñañez I, García-román R. Chronic liver diseases and the potential use of S-adenosyl-l-methionine as a hepatoprotector. European Journal of Gastroenterology & Hepatology 2018;30:893-900. [DOI: 10.1097/meg.0000000000001141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
420 Yeh MM, Brunt EM. Pathology of fatty liver: differential diagnosis of non-alcoholic fatty liver disease. Diagnostic Histopathology 2008;14:586-97. [DOI: 10.1016/j.mpdhp.2008.09.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
421 Wei Y, Clark SE, Thyfault JP, Uptergrove GM, Li W, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol 2009;174:1329-37. [PMID: 19246643 DOI: 10.2353/ajpath.2009.080697] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
422 Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z, Zhou L, Xie H, Zheng S. Metabolic Changes of Hepatocytes in NAFLD. Front Physiol 2021;12:710420. [PMID: 34526911 DOI: 10.3389/fphys.2021.710420] [Reference Citation Analysis]
423 Lucchesi AN, Freitas NTD, Cassettari LL, Marques SFG, Spadella CT. Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease. Acta Cir Bras 2013;28:502-8. [DOI: 10.1590/s0102-86502013000700005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
424 Lemoine M, Serfaty L, Cervera P, Capeau J, Ratziu V. Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage. Hepatol Res 2014;44:1241-7. [PMID: 24118921 DOI: 10.1111/hepr.12244] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
425 Ter Horst KW, Gilijamse PW, Versteeg RI, Ackermans MT, Nederveen AJ, la Fleur SE, Romijn JA, Nieuwdorp M, Zhang D, Samuel VT, Vatner DF, Petersen KF, Shulman GI, Serlie MJ. Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans. Cell Rep 2017;19:1997-2004. [PMID: 28591572 DOI: 10.1016/j.celrep.2017.05.035] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 19.3] [Reference Citation Analysis]
426 Shi Y, Pizzini J, Wang H, Das F, Abdul Azees PA, Ghosh Choudhury G, Barnes JL, Zang M, Weintraub ST, Yeh CK, Katz MS, Kamat A. β2-Adrenergic receptor agonist induced hepatic steatosis in mice: modeling nonalcoholic fatty liver disease in hyperadrenergic states. Am J Physiol Endocrinol Metab 2021;321:E90-E104. [PMID: 34029162 DOI: 10.1152/ajpendo.00651.2020] [Reference Citation Analysis]
427 Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004;34:9-19. [PMID: 15670660 DOI: 10.1016/j.alcohol.2004.07.008] [Cited by in Crossref: 397] [Cited by in F6Publishing: 356] [Article Influence: 23.4] [Reference Citation Analysis]
428 Antonucci L, Porcu C, Iannucci G, Balsano C, Barbaro B. Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper. Nutrients 2017;9:E1137. [PMID: 29057834 DOI: 10.3390/nu9101137] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
429 Lee S, Rivera-Vega M, Alsayed HM, Boesch C, Libman I. Metabolic inflexibility and insulin resistance in obese adolescents with non-alcoholic fatty liver disease. Pediatr Diabetes 2015;16:211-8. [PMID: 24754380 DOI: 10.1111/pedi.12141] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
430 Huang X, Yang G, Zhao L, Yuan H, Chen H, Shen T, Tang W, Man Y, Ma J, Ma Y, Dou L, Li J. Protein Phosphatase 4 Promotes Hepatocyte Lipoapoptosis by Regulating RAC1/MLK3/JNK Pathway. Oxid Med Cell Longev 2021;2021:5550498. [PMID: 34221233 DOI: 10.1155/2021/5550498] [Reference Citation Analysis]
431 Laurent A, Nicco C, Tran Van Nhieu J, Borderie D, Chéreau C, Conti F, Jaffray P, Soubrane O, Calmus Y, Weill B. Pivotal role of superoxide anion and beneficial effect of antioxidant molecules in murine steatohepatitis. Hepatology. 2004;39:1277-1285. [PMID: 15122756 DOI: 10.1002/hep.20177] [Cited by in Crossref: 92] [Cited by in F6Publishing: 92] [Article Influence: 5.1] [Reference Citation Analysis]
432 Sreekumar R. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003;38:244-51. [DOI: 10.1053/jhep.2003.50290] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 6.6] [Reference Citation Analysis]
433 Hong T, Chen Y, Li X, Lu Y. The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD. Oxid Med Cell Longev 2021;2021:6889533. [PMID: 34745420 DOI: 10.1155/2021/6889533] [Reference Citation Analysis]
434 Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol 2014; 20(27): 9072-9089 [PMID: 25083080 DOI: 10.3748/wjg.v20.i27.9072] [Cited by in F6Publishing: 47] [Reference Citation Analysis]
435 Solheim MH, Winnay JN, Batista TM, Molven A, Njølstad PR, Kahn CR. Mice Carrying a Dominant-Negative Human PI3K Mutation Are Protected From Obesity and Hepatic Steatosis but Not Diabetes. Diabetes 2018;67:1297-309. [PMID: 29724723 DOI: 10.2337/db17-1509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
436 Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BWJH, Berk M. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med 2020;18:261. [PMID: 32998725 DOI: 10.1186/s12916-020-01713-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
437 Simoes ICM, Janikiewicz J, Bauer J, Karkucinska-Wieckowska A, Kalinowski P, Dobrzyń A, Wolski A, Pronicki M, Zieniewicz K, Dobrzyń P, Krawczyk M, Zischka H, Wieckowski MR, Potes Y. Fat and Sugar-A Dangerous Duet. A Comparative Review on Metabolic Remodeling in Rodent Models of Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E2871. [PMID: 31771244 DOI: 10.3390/nu11122871] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
438 Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni C. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Research and Clinical Practice 2009;84:84-91. [DOI: 10.1016/j.diabres.2008.11.039] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 8.5] [Reference Citation Analysis]
439 García-Ruiz C, Fernández-Checa JC. Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease. Hepatol Commun 2018;2:1425-39. [PMID: 30556032 DOI: 10.1002/hep4.1271] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
440 Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA. Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. J Nutr Biochem 2012;23:1676-84. [PMID: 22464149 DOI: 10.1016/j.jnutbio.2011.11.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
441 Tagawa R, Kawano Y, Minami A, Nishiumi S, Yano Y, Yoshida M, Kodama Y. β-hydroxybutyrate protects hepatocytes against endoplasmic reticulum stress in a sirtuin 1-independent manner. Arch Biochem Biophys 2019;663:220-7. [PMID: 30664838 DOI: 10.1016/j.abb.2019.01.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
442 Harrison SA, Di Bisceglie AM. Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease: . Drugs 2003;63:2379-94. [DOI: 10.2165/00003495-200363220-00001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
443 Bozic MA, Subbarao G, Molleston JP. Pediatric Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2013;28:448-58. [DOI: 10.1177/0884533613489153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
444 Smith GI, Shankaran M, Yoshino M, Schweitzer GG, Chondronikola M, Beals JW, Okunade AL, Patterson BW, Nyangau E, Field T, Sirlin CB, Talukdar S, Hellerstein MK, Klein S. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J Clin Invest 2020;130:1453-60. [PMID: 31805015 DOI: 10.1172/JCI134165] [Cited by in Crossref: 85] [Cited by in F6Publishing: 54] [Article Influence: 42.5] [Reference Citation Analysis]
445 Neuschwander-Tetri BA. Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH. Curr Gastroenterol Rep. 2010;12:49-56. [PMID: 20425484 DOI: 10.1007/s11894-009-0083-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
446 Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, Zhang L, Wang Y. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci. 2006;79:1100-1107. [PMID: 16624332 DOI: 10.1016/j.lfs.2006.03.021] [Cited by in Crossref: 135] [Cited by in F6Publishing: 137] [Article Influence: 8.4] [Reference Citation Analysis]
447 El-Lakkany NM, Seif El-Din SH, Sabra AA, Hammam OA, Ebeid FA. Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver. Res Pharm Sci 2016;11:374-82. [PMID: 27920819 DOI: 10.4103/1735-5362.192487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
448 Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev. 2010;31:364-395. [PMID: 20156986 DOI: 10.1210/er.2009-0027] [Cited by in Crossref: 334] [Cited by in F6Publishing: 318] [Article Influence: 27.8] [Reference Citation Analysis]
449 Park H, Ishigami A, Shima T, Mizuno M, Maruyama N, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. J Gastroenterol 2010;45:426-34. [DOI: 10.1007/s00535-009-0154-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
450 Morling JR, Fallowfield JA, Williamson RM, Nee LD, Jackson AP, Glancy S, Reynolds RM, Hayes PC, Guha IN, Strachan MWJ, Price JF. Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study. Liver Int 2014;34:1267-77. [DOI: 10.1111/liv.12385] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
451 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
452 Perez A, Anzaldua M, McCormick J, Fisher-Hoch S. High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population. J Gastroenterol Hepatol 2004;19:289-95. [PMID: 14748876 DOI: 10.1111/j.1440-1746.2003.03277.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
453 Pessayre D, Fromenty B, Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol. 2004;16:1095-1105. [PMID: 15489566 DOI: 10.1097/00042737-200411000-00003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 5.8] [Reference Citation Analysis]
454 Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2013;92:114-118. [PMID: 23159641 DOI: 10.1016/j.lfs.2012.11.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
455 You S, Hu X, Zhao Q, Chen X, Xu C. Oat β-glucan inhibits lipopolysaccharide-induced nonalcoholic steatohepatitis in mice. Food Funct 2013;4:1360. [DOI: 10.1039/c3fo60081e] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
456 Gormaz JG, Rodrigo R, Videla LA, Beems M. Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease. Progress in Lipid Research 2010;49:407-19. [DOI: 10.1016/j.plipres.2010.05.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
457 Dongiovanni P, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. The Journal of Nutritional Biochemistry 2016;29:1-11. [DOI: 10.1016/j.jnutbio.2015.08.024] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
458 Gastaldelli A, Natali A, Vettor R, Corradini SG. Insulin resistance, adipose depots and gut: Interactions and pathological implications. Digestive and Liver Disease 2010;42:310-9. [DOI: 10.1016/j.dld.2010.01.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
459 Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96. [PMID: 14752837 DOI: 10.1002/hep.20012] [Cited by in Crossref: 543] [Cited by in F6Publishing: 472] [Article Influence: 30.2] [Reference Citation Analysis]
460 Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-49. [PMID: 17845148 DOI: 10.1517/14728222.11.9.1231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
461 Abbate M, Montemayor S, Mascaró CM, Casares M, Gómez C, Ugarriza L, Tejada S, Abete I, Zulet MÁ, Sureda A, Martínez JA, Tur JA. Albuminuria Is Associated with Hepatic Iron Load in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome. J Clin Med 2021;10:3187. [PMID: 34300354 DOI: 10.3390/jcm10143187] [Reference Citation Analysis]
462 Froylich D, Corcelles R, Daigle C, Boules M, Brethauer S, Schauer P. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12:127-131. [PMID: 26077701 DOI: 10.1016/j.soard.2015.04.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
463 Qin G, Wu M, Wang J, Xu Z, Xia J, Sang N. Sulfur Dioxide Contributes to the Cardiac and Mitochondrial Dysfunction in Rats. Toxicol Sci 2016;151:334-46. [PMID: 26980303 DOI: 10.1093/toxsci/kfw048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
464 Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013;52:165-74. [PMID: 23178552 DOI: 10.1016/j.plipres.2012.10.004] [Cited by in Crossref: 232] [Cited by in F6Publishing: 231] [Article Influence: 23.2] [Reference Citation Analysis]
465 Grattagliano I, Caraceni P, Calamita G, Ferri D, Gargano I, Palasciano G, Portincasa P. Severe liver steatosis correlates with nitrosative and oxidative stress in rats. Eur J Clin Invest. 2008;38:523-530. [PMID: 18578693 DOI: 10.1111/j.1365-2362.2008.01963.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
466 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 11.7] [Reference Citation Analysis]
467 Nadal-Casellas A, Proenza AM, Lladó I, Gianotti M. Sex-dependent differences in rat hepatic lipid accumulation and insulin sensitivity in response to diet-induced obesity. Biochem Cell Biol 2012;90:164-72. [PMID: 22235846 DOI: 10.1139/o11-069] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
468 Sajjad A, Mottershead M, Syn WK, Jones R, Smith S, Nwokolo CU. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2005;22:291-299. [PMID: 16097995 DOI: 10.1111/j.1365-2036.2005.02562.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
469 Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011;42:337-353. [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
470 Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006;131:934-945. [PMID: 16952562 DOI: 10.1053/j.gastro.2006.05.054] [Cited by in Crossref: 241] [Cited by in F6Publishing: 229] [Article Influence: 15.1] [Reference Citation Analysis]
471 Puri P, Sanyal AJ. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2018;22:121-32. [PMID: 29128052 DOI: 10.1016/j.cld.2017.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
472 Panasiuk A, Dzieciol J, Panasiuk B, Prokopowicz D. Expression of p53, Bax and Bcl-2 proteins in hepatocytes in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12(38): 6198-6202 [PMID: 17036395 DOI: 10.3748/wjg.v12.i38.6198] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 58] [Article Influence: 3.5] [Reference Citation Analysis]
473 Hadi A, Arab A, Hajianfar H, Talaei B, Miraghajani M, Babajafari S, Marx W, Tavakoly R. The effect of fenugreek seed supplementation on serum irisin levels, blood pressure, and liver and kidney function in patients with type 2 diabetes mellitus: A parallel randomized clinical trial. Complementary Therapies in Medicine 2020;49:102315. [DOI: 10.1016/j.ctim.2020.102315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
474 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
475 Quiles JL, Ochoa JJ, Ramirez-Tortosa MC, Huertas JR, Mataix J. Age-related mitochondrial DNA deletion in rat liver depends on dietary fat unsaturation. J Gerontol A Biol Sci Med Sci 2006;61:107-14. [PMID: 16510854 DOI: 10.1093/gerona/61.2.107] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
476 Ko JS. Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2010;56:6. [DOI: 10.4166/kjg.2010.56.1.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
477 Tahan V, Eren F, Avsar E, Yavuz D, Yuksel M, Emekli E, Imeryuz N, Celikel C, Uzun H, Haklar G. Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis. Dig Dis Sci. 2007;52:3465-3472. [PMID: 17436085 DOI: 10.1007/s10620-007-9756-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
478 Bo S, Durazzo M, Guidi S, Carello M, Sacerdote C, Silli B, Rosato R, Cassader M, Gentile L, Pagano G. Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. The American Journal of Clinical Nutrition 2006;84:1062-9. [DOI: 10.1093/ajcn/84.5.1062] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 5.6] [Reference Citation Analysis]
479 Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 2009;87:679-695. [PMID: 19352614 DOI: 10.1007/s00109-009-0464-1] [Cited by in Crossref: 188] [Cited by in F6Publishing: 174] [Article Influence: 14.5] [Reference Citation Analysis]
480 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2003; 11(7): 1043-1045 [DOI: 10.11569/wcjd.v11.i7.1043] [Reference Citation Analysis]
481 Jawad R, D’souza M, Selenius LA, Lundgren MW, Danielsson O, Nowak G, Björnstedt M, Isaksson B. Morphological alterations and redox changes associated with hepatic warm ischemia-reperfusion injury. World J Hepatol 2017; 9(34): 1261-1269 [PMID: 29290907 DOI: 10.4254/wjh.v9.i34.1261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
482 Le TH, Caldwell SH, Redick JA, Sheppard BL, Davis CA, Arseneau KO, Iezzoni JC, Hespenheide EE, Al-Osaimi A, Peterson TC. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology. 2004;39:1423-1429. [PMID: 15122772 DOI: 10.1002/hep.20202] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
483 Ackerman Z, Oron-Herman M, Grozovski M, Rosenthal T, Pappo O, Link G, Sela BA. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension. 2005;45:1012-1018. [PMID: 15824194 DOI: 10.1161/01.hyp.0000164570.20420.67] [Cited by in Crossref: 150] [Cited by in F6Publishing: 69] [Article Influence: 8.8] [Reference Citation Analysis]
484 Cazanave SC, Gores GJ. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol. 2010;5:71-85. [PMID: 20368747 DOI: 10.2217/clp.09.85] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 5.7] [Reference Citation Analysis]
485 Fabbrini E, Magkos F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients 2015;7:4995-5019. [PMID: 26102213 DOI: 10.3390/nu7064995] [Cited by in Crossref: 90] [Cited by in F6Publishing: 82] [Article Influence: 12.9] [Reference Citation Analysis]
486 Nakamoto K, Takayama F, Mankura M, Hidaka Y, Egashira T, Ogino T, Kawasaki H, Mori A. Beneficial Effects of Fermented Green Tea Extract in a Rat Model of Non-alcoholic Steatohepatitis. J Clin Biochem Nutr 2009;44:239-46. [PMID: 19430612 DOI: 10.3164/jcbn.08-256] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
487 Deng Z, Yan S, Hu H, Duan Z, Yin L, Liao S, Sun Y, Yin D, Li G. Proteomic profile of carbonylated proteins in rat liver: discovering possible mechanisms for tetracycline-induced steatosis. Proteomics 2015;15:148-59. [PMID: 25332112 DOI: 10.1002/pmic.201400115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
488 Clemente Ricote G, García Monzón C. Estado actual de la esteatohepatitis no alcohólica. Medicina Clínica 2003;121:102-8. [DOI: 10.1016/s0025-7753(03)73870-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
489 Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:575-594, ix. [PMID: 15331065 DOI: 10.1016/j.cld.2004.04.006] [Cited by in Crossref: 100] [Cited by in F6Publishing: 90] [Article Influence: 5.6] [Reference Citation Analysis]
490 Te Sligte K, Bourass I, Sels JP, Driessen A, Stockbrugger RW, Koek GH. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med. 2004;15:10-21. [PMID: 15066643 DOI: 10.1016/j.ejim.2003.12.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 3.8] [Reference Citation Analysis]
491 Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: Prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005;42:310-6. [DOI: 10.1002/hep.20805] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 3.1] [Reference Citation Analysis]
492 Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-379. [PMID: 11826411 DOI: 10.1053/jhep.2002.30692] [Cited by in Crossref: 774] [Cited by in F6Publishing: 739] [Article Influence: 38.7] [Reference Citation Analysis]
493 Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, dela Pena A, Bell-anderson KS, Farrell GC. Activation of peroxisome proliferator-activated receptor α by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol 2008;23:267-75. [DOI: 10.1111/j.1440-1746.2007.05157.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 3.8] [Reference Citation Analysis]
494 Green CJ, Parry SA, Gunn PJ, Ceresa CDL, Rosqvist F, Piché ME, Hodson L. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Horm Mol Biol Clin Investig 2018;41:/j/hmbci. [PMID: 30098284 DOI: 10.1515/hmbci-2018-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
495 Zhang D, Xie L, Jia G, Cai S, Ji B, Liu Y, Wu W, Zhou F, Wang A, Chu L, Wei Y, Liu J, Gao F. Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro. Eur J Med Chem 2011;46:4548-58. [PMID: 21824690 DOI: 10.1016/j.ejmech.2011.07.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
496 Machado M, Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care. 2006;9:637-642. [PMID: 16912563 DOI: 10.1097/01.mco.0000241677.40170.17] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
497 Haghighatdoost F, Salehi-Abargouei A, Surkan PJ, Azadbakht L. The effects of low carbohydrate diets on liver function tests in nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials. J Res Med Sci 2016;21:53. [PMID: 27904598 DOI: 10.4103/1735-1995.187269] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
498 Ravi Kanth VV, Sasikala M, Sharma M, Rao PN, Reddy DN. Genetics of non-alcoholic fatty liver disease: From susceptibility and nutrient interactions to management. World J Hepatol 2016; 8(20): 827-837 [PMID: 27458502 DOI: 10.4254/wjh.v8.i20.827] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
499 Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW, Thyfault JP, Ibdah JA. Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model. Am J Physiol Gastrointest Liver Physiol. 2011;300:G874-G883. [PMID: 21350190 DOI: 10.1152/ajpgi.00510.2010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 8.6] [Reference Citation Analysis]
500 Bhowmick S, Singh V, Jash S, Lal M, Sinha Roy S. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma. Mitochondrion 2021;58:24-37. [PMID: 33581332 DOI: 10.1016/j.mito.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006;25:816-823. [PMID: 16677739 DOI: 10.1016/j.clnu.2006.01.027] [Cited by in Crossref: 162] [Cited by in F6Publishing: 155] [Article Influence: 10.1] [Reference Citation Analysis]
502 Cao X, Yang F, Shi T, Yuan M, Xin Z, Xie R, Li S, Li H, Yang JK. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis. Sci Rep. 2016;6:21592. [PMID: 26883384 DOI: 10.1038/srep21592] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
503 Sumida Y, Yoshikawa T, Okanoue T. Role of hepatic iron in non-alcoholic steatohepatitis. Hepatol Res. 2009;39:213-222. [PMID: 19261002 DOI: 10.1111/j.1872-034x.2008.00442.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
504 Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, Sanyal AJ, Kowdley KV, Neuschwander-Tetri BA, Brunt EM. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56:1311-1318. [PMID: 22532269 DOI: 10.1002/hep.25805] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
505 Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79. [PMID: 12512031 DOI: 10.1053/gast.2003.50004] [Cited by in Crossref: 405] [Cited by in F6Publishing: 364] [Article Influence: 21.3] [Reference Citation Analysis]
506 Kuppan G, Anjana RM, Deepa M, Paramasivam P, Chandrakumar S, Kaliyaperumal V, Mohan V. Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. Diabetes Technol Ther 2012;14:152-8. [PMID: 22149546 DOI: 10.1089/dia.2011.0213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
507 Cheng S, Yang Y, Zhou Y, Xiang W, Yao H, Ma L. Influence of different concentrations of uric acid on oxidative stress in steatosis hepatocytes. Exp Ther Med 2018;15:3659-65. [PMID: 29545896 DOI: 10.3892/etm.2018.5855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
508 Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: The metabolic movers. Journal of Gastroenterology and Hepatology 2010;25:672-90. [DOI: 10.1111/j.1440-1746.2010.06253.x] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 10.3] [Reference Citation Analysis]
509 Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, Hasegawa T, Aoshima M, Miyokawa N, Haneda M, Yoneda M. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol 2006; 12(2): 322-326 [PMID: 16482638 DOI: 10.3748/wjg.v12.i2.322] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
510 Sid V, Siow YL, O K. Role of folate in nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2017;95:1141-1148. [PMID: 28460180 DOI: 10.1139/cjpp-2016-0681] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
511 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
512 Noureddin M, Muthiah MD, Sanyal AJ. Drug discovery and treatment paradigms in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00105. [PMID: 33102791 DOI: 10.1002/edm2.105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
513 Gusdon AM, Song KX, Qu S. Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective. Oxid Med Cell Longev 2014;2014:637027. [PMID: 25371775 DOI: 10.1155/2014/637027] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
514 Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab. 2002;16:703-716. [PMID: 12468416 DOI: 10.1053/beem.2002.0225] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.3] [Reference Citation Analysis]
515 Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D. The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab. 2004;30:121-138. [PMID: 15223984 DOI: 10.1016/s1262-3636(07)70098-8] [Cited by in Crossref: 177] [Cited by in F6Publishing: 67] [Article Influence: 9.8] [Reference Citation Analysis]
516 Wu SD, Li L, Wang JY. Ursodeoxycholic acid for nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2012;24:1247-1253. [PMID: 22864259 DOI: 10.1097/meg.0b013e3283572ec0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
517 Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18:124-138. [PMID: 12542595 DOI: 10.1046/j.1440-1746.2003.02989.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 146] [Article Influence: 8.4] [Reference Citation Analysis]
518 Lee H, Yoon Y. Mitochondrial fission and fusion. Biochem Soc Trans 2016;44:1725-35. [PMID: 27913683 DOI: 10.1042/BST20160129] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 14.8] [Reference Citation Analysis]
519 Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905. [PMID: 15795412 DOI: 10.1503/cmaj.045232] [Cited by in Crossref: 330] [Cited by in F6Publishing: 313] [Article Influence: 19.4] [Reference Citation Analysis]
520 García-Ruiz I, Solís-Muñoz P, Fernández-Moreira D, Grau M, Colina F, Muñoz-Yagüe T, Solís-Herruzo JA. High-fat diet decreases activity of the oxidative phosphorylation complexes and causes nonalcoholic steatohepatitis in mice. Dis Model Mech 2014;7:1287-96. [PMID: 25261569 DOI: 10.1242/dmm.016766] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
521 Oliveira CP, Stefano JT, Cavaleiro AM, Zanella Fortes MA, Vieira SM, Rodrigues Lima VM, Santos TE, Santos VN, de Azevedo Salgado AL, Parise ER, Ferreira Alves VA, Carrilho FJ, Corrêa-Giannella ML. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2010;25:357-61. [PMID: 19817962 DOI: 10.1111/j.1440-1746.2009.06001.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
522 Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes. 2014;4:243-253. [PMID: 25825857 DOI: 10.1111/cob.12068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
523 El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel) 2018;7:E12. [PMID: 29337849 DOI: 10.3390/antiox7010012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
524 Fabbrini E, Yoshino J, Yoshino M, Magkos F, Tiemann Luecking C, Samovski D, Fraterrigo G, Okunade AL, Patterson BW, Klein S. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest. 2015;125:787-795. [PMID: 25555214 DOI: 10.1172/jci78425] [Cited by in Crossref: 104] [Cited by in F6Publishing: 68] [Article Influence: 14.9] [Reference Citation Analysis]
525 Jung YA, Choi YK, Jung GS, Seo HY, Kim HS, Jang BK, Kim JG, Lee IK, Kim MK, Park KG. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis. Diabetes Res Clin Pract. 2014;105:47-57. [PMID: 24842243 DOI: 10.1016/j.diabres.2014.04.028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
526 Zivkovic AM, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. The American Journal of Clinical Nutrition 2007;86:285-300. [DOI: 10.1093/ajcn/86.2.285] [Cited by in Crossref: 256] [Cited by in F6Publishing: 236] [Article Influence: 17.1] [Reference Citation Analysis]
527 von Loeffelholz C, Coldewey SM, Birkenfeld AL. A Narrative Review on the Role of AMPK on De Novo Lipogenesis in Non-Alcoholic Fatty Liver Disease: Evidence from Human Studies. Cells 2021;10:1822. [PMID: 34359991 DOI: 10.3390/cells10071822] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
528 Zgheib NK, Branch RA. Drug metabolism and liver disease: a drug-gene-environment interaction. Drug Metab Rev 2017;49:35-55. [PMID: 27957864 DOI: 10.1080/03602532.2016.1271807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
529 Harrison SA, Neuschwander-tetri BA. Pharmacologic management of nonalcoholic fatty liver disease. Clinics in Liver Disease 2004;8:715-28. [DOI: 10.1016/j.cld.2004.04.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
530 Pirola CJ, Scian R, Gianotti TF, Dopazo H, Rohr C, Martino JS, Castaño GO, Sookoian S. Epigenetic Modifications in the Biology of Nonalcoholic Fatty Liver Disease: The Role of DNA Hydroxymethylation and TET Proteins. Medicine (Baltimore) 2015;94:e1480. [PMID: 26356709 DOI: 10.1097/MD.0000000000001480] [Cited by in Crossref: 44] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
531 Ryoo JH, Hong HP, Park SK, Ham WT, Chung JY. The Risk for Insulin Resistance according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men. J Korean Med Sci 2016;31:1761-7. [PMID: 27709854 DOI: 10.3346/jkms.2016.31.11.1761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
532 Nuño-Lámbarri N, Barbero-Becerra VJ, Uribe M, Chávez-Tapia NC. Mitochondrial Molecular Pathophysiology of Nonalcoholic Fatty Liver Disease: A Proteomics Approach. Int J Mol Sci 2016;17:281. [PMID: 26999105 DOI: 10.3390/ijms17030281] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
533 Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008;49:1068-1076. [PMID: 18227531 DOI: 10.1194/jlr.m800042-jlr200] [Cited by in Crossref: 273] [Cited by in F6Publishing: 169] [Article Influence: 19.5] [Reference Citation Analysis]
534 Wan X, Xu C, Yu C, Li Y. Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH. Can J Gastroenterol Hepatol 2016;2016:6489012. [PMID: 27446858 DOI: 10.1155/2016/6489012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 8.7] [Reference Citation Analysis]
535 Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, Oh Y, Puri P, Sanyal AJ. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J 2016;30:4071-82. [PMID: 27553225 DOI: 10.1096/fj.201600427R] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
536 de Luis DA, Aller R, Izaola O, Sagrado MG, Conde R, Bellido D. Influence of Insulin Resistance and Adipocytokines on Elevated Serum Alanine Aminotransferase in Obese Patients. Archives of Medical Research 2008;39:110-4. [DOI: 10.1016/j.arcmed.2007.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
537 Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007;47:142-156. [PMID: 17512085 DOI: 10.1016/j.jhep.2007.04.002] [Cited by in Crossref: 210] [Cited by in F6Publishing: 199] [Article Influence: 14.0] [Reference Citation Analysis]
538 Kim JE, Clark RM, Park Y, Lee J, Fernandez ML. Lutein decreases oxidative stress and inflammation in liver and eyes of guinea pigs fed a hypercholesterolemic diet. Nutr Res Pract 2012;6:113-9. [PMID: 22586499 DOI: 10.4162/nrp.2012.6.2.113] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
539 Manco M, Bottazzo G, Devito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic Fatty Liver Disease in Children. Journal of the American College of Nutrition 2008;27:667-76. [DOI: 10.1080/07315724.2008.10719744] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
540 Phielix E, Szendroedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci. 2011;32:607-616. [PMID: 21824668 DOI: 10.1016/j.tips.2011.06.006] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 5.7] [Reference Citation Analysis]
541 Hotta K, Kikuchi M, Kitamoto T, Kitamoto A, Ogawa Y, Honda Y, Kessoku T, Kobayashi K, Yoneda M, Imajo K, Tomeno W, Nakaya A, Suzuki Y, Saito S, Nakajima A. Identification of core gene networks and hub genes associated with progression of non-alcoholic fatty liver disease by RNA sequencing. Hepatol Res 2017;47:1445-58. [PMID: 28219123 DOI: 10.1111/hepr.12877] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
542 Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007;46:1081-90. [DOI: 10.1002/hep.21763] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
543 Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism 2016;65:1049-61. [PMID: 26997538 DOI: 10.1016/j.metabol.2016.02.014] [Cited by in Crossref: 169] [Cited by in F6Publishing: 163] [Article Influence: 28.2] [Reference Citation Analysis]
544 Zhang HF, Shi LJ, Song GY, Cai ZG, Wang C, An RJ. Protective effects of matrine against progression of high-fructose diet-induced steatohepatitis by enhancing antioxidant and anti-inflammatory defences involving Nrf2 translocation. Food Chem Toxicol 2013;55:70-7. [PMID: 23295629 DOI: 10.1016/j.fct.2012.12.043] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
545 Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812-41. [PMID: 22829562 DOI: 10.1210/er.2012-1003] [Cited by in Crossref: 153] [Cited by in F6Publishing: 136] [Article Influence: 15.3] [Reference Citation Analysis]
546 Rodríguez-Hernández H, Gonzalez JL, Rodríguez-Morán M, Guerrero-Romero F. Hypomagnesemia, insulin resistance, and non-alcoholic steatohepatitis in obese subjects. Arch Med Res 2005;36:362-6. [PMID: 15950075 DOI: 10.1016/j.arcmed.2005.03.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
547 Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40:1367-1393. [PMID: 31098621 DOI: 10.1210/er.2019-00034] [Cited by in Crossref: 66] [Cited by in F6Publishing: 71] [Article Influence: 33.0] [Reference Citation Analysis]
548 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839.2014.12.06] [Cited by in F6Publishing: 76] [Reference Citation Analysis]
549 Sung KC, Lee MY, Lee JY, Lee SH, Kim YB, Song WJ, Huh JH, Park JS, Shin JH, Seo MH, Kim SH, Kim SH. Natural course of fatty liver in 36,195 South Korean adults. Sci Rep 2019;9:9062. [PMID: 31308382 DOI: 10.1038/s41598-019-44738-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
550 Videla LA, Rodrigo R, Araya J, Poniachik J. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease. Free Radic Biol Med. 2004;37:1499-1507. [PMID: 15454290 DOI: 10.1016/j.freeradbiomed.2004.06.033] [Cited by in Crossref: 165] [Cited by in F6Publishing: 161] [Article Influence: 9.7] [Reference Citation Analysis]
551 Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008;14:72-81. [PMID: 18218340 DOI: 10.1016/j.molmed.2007.12.003] [Cited by in Crossref: 293] [Cited by in F6Publishing: 288] [Article Influence: 20.9] [Reference Citation Analysis]
552 Puri P, Daita K, Joyce A, Mirshahi F, Santhekadur PK, Cazanave S, Luketic VA, Siddiqui MS, Boyett S, Min HK, Kumar DP, Kohli R, Zhou H, Hylemon PB, Contos MJ, Idowu M, Sanyal AJ. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018;67:534-548. [PMID: 28696585 DOI: 10.1002/hep.29359] [Cited by in Crossref: 129] [Cited by in F6Publishing: 129] [Article Influence: 25.8] [Reference Citation Analysis]
553 Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011;301:G825-34. [PMID: 21836057 DOI: 10.1152/ajpgi.00145.2011] [Cited by in Crossref: 260] [Cited by in F6Publishing: 225] [Article Influence: 23.6] [Reference Citation Analysis]
554 Gariani K, Menzies KJ, Ryu D, Wegner CJ, Wang X, Ropelle ER, Moullan N, Zhang H, Perino A, Lemos V, Kim B, Park YK, Piersigilli A, Pham TX, Yang Y, Ku CS, Koo SI, Fomitchova A, Cantó C, Schoonjans K, Sauve AA, Lee JY, Auwerx J. Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology 2016;63:1190-204. [PMID: 26404765 DOI: 10.1002/hep.28245] [Cited by in Crossref: 190] [Cited by in F6Publishing: 182] [Article Influence: 27.1] [Reference Citation Analysis]
555 Moro T, Nakao S, Sumiyoshi H, Ishii T, Miyazawa M, Ishii N, Sato T, Iida Y, Okada Y, Tanaka M, Hayashi H, Ueha S, Matsushima K, Inagaki Y. A Combination of Mitochondrial Oxidative Stress and Excess Fat/Calorie Intake Accelerates Steatohepatitis by Enhancing Hepatic CC Chemokine Production in Mice. PLoS One 2016;11:e0146592. [PMID: 26745268 DOI: 10.1371/journal.pone.0146592] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
556 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 247] [Cited by in F6Publishing: 231] [Article Influence: 24.7] [Reference Citation Analysis]
557 Yang DK, Jo DG. Mulberry Fruit Extract Ameliorates Nonalcoholic Fatty Liver Disease (NAFLD) through Inhibition of Mitochondrial Oxidative Stress in Rats. Evid Based Complement Alternat Med 2018;2018:8165716. [PMID: 30643537 DOI: 10.1155/2018/8165716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
558 Burke A, Lucey MR. Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis and Orthotopic Liver Transplantation. Am J Transplant 2004;4:686-93. [DOI: 10.1111/j.1600-6143.2004.00432.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 123] [Article Influence: 8.3] [Reference Citation Analysis]
559 Mandala A, Janssen RC, Palle S, Short KR, Friedman JE. Pediatric Non-Alcoholic Fatty Liver Disease: Nutritional Origins and Potential Molecular Mechanisms. Nutrients 2020;12:E3166. [PMID: 33081177 DOI: 10.3390/nu12103166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
560 Hashemi Kani A, Alavian SM, Haghighatdoost F, Azadbakht L. Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents. Hepat Mon. 2014;14:e10939. [PMID: 24693306 DOI: 10.5812/hepatmon.10939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
561 Cortez-pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Practice & Research Clinical Gastroenterology 2004;18:1089-104. [DOI: 10.1016/j.bpg.2004.06.021] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
562 Katsanos CS. Lipid-Induced Insulin Resistance in the Liver: Role of Exercise. Sports Medicine 2004;34:955-65. [DOI: 10.2165/00007256-200434140-00002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
563 Reiniers MJ, van Golen RF, van Gulik TM, Heger M. Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver. Antioxid Redox Signal. 2014;21:1119-1142. [PMID: 24294945 DOI: 10.1089/ars.2013.5486] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
564 Jeon BT, Heo RW, Shin HJ, Yi CO, Lee YH, Joung HN, Jung JH, Jung J, Kim SK, Hahm JR, Lee BW, Ko JM, Baek IY, Kang SS, Roh GS. Attenuation by a Vigna nakashimae extract of nonalcoholic fatty liver disease in high-fat diet-fed mice. Biosci Biotechnol Biochem 2014;78:482-9. [PMID: 25036839 DOI: 10.1080/09168451.2014.882753] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
565 Khashab M, Chalasani N. Use of insulin sensitizers in NASH. Endocrinol Metab Clin North Am 2007;36:1067-87; xi. [PMID: 17983937 DOI: 10.1016/j.ecl.2007.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
566 Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. Journal of Hepatology 2006;44:1167-74. [DOI: 10.1016/j.jhep.2006.02.011] [Cited by in Crossref: 347] [Cited by in F6Publishing: 348] [Article Influence: 21.7] [Reference Citation Analysis]
567 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine 2012;52:59-69. [DOI: 10.1016/j.freeradbiomed.2011.10.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 519] [Article Influence: 53.9] [Reference Citation Analysis]
568 Hu YB. Mechanisms of non-alcoholic steatohepatitis: pathophysiology and molecular biology. Shijie Huaren Xiaohua Zazhi 2009; 17(13): 1329-1334 [DOI: 10.11569/wcjd.v17.i13.1329] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
569 Hur W, Kim SW, Lee YK, Choi JE, Hong SW, Song MJ, Bae SH, Park T, Um S, Yoon SK. Oleuropein reduces free fatty acid-induced lipogenesis via lowered extracellular signal-regulated kinase activation in hepatocytes. Nutrition Research 2012;32:778-86. [DOI: 10.1016/j.nutres.2012.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
570 Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver disease. Adv Immunol. 2013;117:73-97. [PMID: 23611286 DOI: 10.1016/b978-0-12-410524-9.00003-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
571 Day CP. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis. 2004;8:673-691, xi. [PMID: 15331069 DOI: 10.1016/j.cld.2004.04.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
572 Vinciguerra M, Foti M. PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling. Arch Physiol Biochem. 2006;112:89-104. [PMID: 16931451 DOI: 10.1080/13813450600711359] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 3.7] [Reference Citation Analysis]
573 De Lorenzo A, Soldati L, Sarlo F, Calvani M, Di Lorenzo N, Di Renzo L. New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol 2016; 22(2): 681-703 [PMID: 26811617 DOI: 10.3748/wjg.v22.i2.681] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 86] [Article Influence: 17.7] [Reference Citation Analysis]
574 Yang Y, Kim B, Park YK, Koo SI, Lee JY. Astaxanthin prevents TGFβ1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. Biochim Biophys Acta. 2015;1850:178-185. [PMID: 25450180 DOI: 10.1016/j.bbagen.2014.10.014] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
575 Zhang ZB, Sun XQ, Qian F, Xue BY. Role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2011; 19(19): 2036-2042 [DOI: 10.11569/wcjd.v19.i19.2036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
576 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
577 Chen J, Wu L, Yang G, Zhang C, Liu X, Sun X, Chen X, Wang N. The influence of PM2.5 exposure on non-alcoholic fatty liver disease. Life Sci 2021;270:119135. [PMID: 33513397 DOI: 10.1016/j.lfs.2021.119135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
578 Ratziu V, Tahiri M, Bonyhay L. La stéatohépatite non alcoolique. Annales d'Endocrinologie 2005;66:71-80. [DOI: 10.1016/s0003-4266(05)81735-4] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
579 Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2011;5:233-244. [PMID: 21476918 DOI: 10.1586/egh.11.11] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
580 Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opin Drug Discov 2021;16:125-34. [PMID: 33086894 DOI: 10.1080/17460441.2020.1811674] [Reference Citation Analysis]
581 Alkhouri N, Dixon LJ, Feldstein AE. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 2009;3:445-51. [PMID: 19673631 DOI: 10.1586/egh.09.32] [Cited by in Crossref: 233] [Cited by in F6Publishing: 221] [Article Influence: 17.9] [Reference Citation Analysis]
582 Mizrahi M, Shabat Y, Ben Ya'acov A, Lalazar G, Adar T, Wong V, Muller B, Rawlin G, Ilan Y. Alleviation of insulin resistance and liver damage by oral administration of Imm124-E is mediated by increased Tregs and associated with increased serum GLP-1 and adiponectin: results of a phase I/II clinical trial in NASH. J Inflamm Res 2012;5:141-50. [PMID: 23293533 DOI: 10.2147/JIR.S35227] [Cited by in Crossref: 7] [Cited by in F6Publishing: 32] [Article Influence: 0.7] [Reference Citation Analysis]
583 Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Gianotti TF, Martino JS, Castaño GO, Pirola CJ. Mitochondrial genome architecture in non-alcoholic fatty liver disease. J Pathol 2016;240:437-49. [PMID: 27577682 DOI: 10.1002/path.4803] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
584 Giorgi C, Marchi S, Simoes ICM, Ren Z, Morciano G, Perrone M, Patalas-Krawczyk P, Borchard S, Jędrak P, Pierzynowska K, Szymański J, Wang DQ, Portincasa P, Węgrzyn G, Zischka H, Dobrzyn P, Bonora M, Duszynski J, Rimessi A, Karkucinska-Wieckowska A, Dobrzyn A, Szabadkai G, Zavan B, Oliveira PJ, Sardao VA, Pinton P, Wieckowski MR. Mitochondria and Reactive Oxygen Species in Aging and Age-Related Diseases. Int Rev Cell Mol Biol 2018;340:209-344. [PMID: 30072092 DOI: 10.1016/bs.ircmb.2018.05.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 16.3] [Reference Citation Analysis]
585 Younossi ZM, Gorreta F, Ong JP, Schlauch K, Del Giacco L, Elariny H, Van Meter A, Younoszai A, Goodman Z, Baranova A. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760-771. [PMID: 15998427 DOI: 10.1111/j.1478-3231.2005.01117.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
586 Manti S, Romano C, Chirico V, Filippelli M, Cuppari C, Loddo I, Salpietro C, Arrigo T. Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic “mal-programming”. Hepat Mon. 2014;14:e17641. [PMID: 24829591 DOI: 10.5812/hepatmon.17641] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
587 Pihlajamäki J, Boes T, Kim EY, Dearie F, Kim BW, Schroeder J, Mun E, Nasser I, Park PJ, Bianco AC. Thyroid hormone-related regulation of gene expression in human fatty liver. J Clin Endocrinol Metab. 2009;94:3521-3529. [PMID: 19549744 DOI: 10.1210/jc.2009-0212] [Cited by in Crossref: 100] [Cited by in F6Publishing: 101] [Article Influence: 7.7] [Reference Citation Analysis]
588 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019;1:312-28. [PMID: 32039382 DOI: 10.1016/j.jhepr.2019.07.002] [Cited by in Crossref: 81] [Cited by in F6Publishing: 65] [Article Influence: 27.0] [Reference Citation Analysis]
589 Vig S, Talwar P, Kaur K, Srivastava R, Srivastava AK, Datta M. Transcriptome profiling identifies p53 as a key player during calreticulin deficiency: Implications in lipid accumulation. Cell Cycle 2015;14:2274-84. [PMID: 25946468 DOI: 10.1080/15384101.2015.1046654] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
590 Han J, Guo X, Koyama T, Kawai D, Zhang J, Yamaguchi R, Zhou X, Motoo Y, Satoh T, Yamada S. Zonarol Protected Liver from Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease in a Mouse Model. Nutrients 2021;13:3455. [PMID: 34684455 DOI: 10.3390/nu13103455] [Reference Citation Analysis]
591 Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008;29:939-60. [DOI: 10.1210/er.2008-0009] [Cited by in Crossref: 338] [Cited by in F6Publishing: 318] [Article Influence: 24.1] [Reference Citation Analysis]
592 Sang C, Wang X, Zhou K, Sun T, Bian H, Gao X, Wang Y, Zhang H, Jia W, Liu P, Xie G, Chen T. Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease. J Proteome Res 2021;20:2340-51. [PMID: 33754726 DOI: 10.1021/acs.jproteome.0c00852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
593 Grattagliano I, Diogo CV, Mastrodonato M, de Bari O, Persichella M, Wang DQ, Liquori A, Ferri D, Carratù MR, Oliveira PJ, Portincasa P. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World J Gastroenterol 2013; 19(20): 3007-3017 [PMID: 23716980 DOI: 10.3748/wjg.v19.i20.3007] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
594 Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, Kendrick M, Thompson G, Que F, Swain J. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology. 2009;49:1375-1384. [PMID: 19330863 DOI: 10.1002/hep.22927] [Cited by in Crossref: 85] [Cited by in F6Publishing: 85] [Article Influence: 6.5] [Reference Citation Analysis]
595 Chalasani NP, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, Unalp A, Tonascia J. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials. 2009;30:88-96. [PMID: 18804555 DOI: 10.1016/j.cct.2008.09.00] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
596 Morita M, Ishida N, Uchiyama K, Yamaguchi K, Itoh Y, Shichiri M, Yoshida Y, Hagihara Y, Naito Y, Yoshikawa T. Fatty liver induced by free radicals and lipid peroxidation. Free Radic Res. 2012;46:758-765. [PMID: 22468959 DOI: 10.3109/10715762.2012.677840] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
597 Zhang Z, Liu S, Qi Y, Aluo Z, Zhang L, Yu L, Li Q, Luo Z, Sun Z, Zhou L, Li Y. Calcium supplementation relieves high-fat diet-induced liver steatosis by reducing energy metabolism and promoting lipolysis. J Nutr Biochem 2021;94:108645. [PMID: 33838230 DOI: 10.1016/j.jnutbio.2021.108645] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
598 Azzu V, Vacca M, Virtue S, Allison M, Vidal-Puig A. Adipose Tissue-Liver Cross Talk in the Control of Whole-Body Metabolism: Implications in Nonalcoholic Fatty Liver Disease. Gastroenterology 2020;158:1899-912. [PMID: 32061598 DOI: 10.1053/j.gastro.2019.12.054] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 17.0] [Reference Citation Analysis]
599 Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, Coban S, Erden E, Soykan I, Emral R. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2008;28:200-208. [PMID: 18445142 DOI: 10.1111/j.1365-2036.2008.03723.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
600 Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterology 2003;98:175-9. [DOI: 10.1111/j.1572-0241.2003.07175.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
601 Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin Drug Saf 2013;12:65-79. [PMID: 23134541 DOI: 10.1517/14740338.2013.741585] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
602 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
603 Chen W, Wang M, Jing X, Wu C, Zeng Y, Peng J, Cai X. High risk of colorectal polyps in men with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2020;35:2051-65. [PMID: 32579269 DOI: 10.1111/jgh.15158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
604 Cortez-pinto H, Machado M. Impact of body weight, diet and lifestyle on nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2014;2:217-31. [DOI: 10.1586/17474124.2.2.217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
605 Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, Berria R, Buzzigoli E, Sironi AM, Cersosimo E, Ferrannini E. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology. 2007;133:496-506. [PMID: 17681171 DOI: 10.1053/j.gastro.2007.04.068] [Cited by in Crossref: 350] [Cited by in F6Publishing: 340] [Article Influence: 23.3] [Reference Citation Analysis]
606 Aller R, de Luis DA, Fernandez L, Calle F, Velayos B, Olcoz JL, Izaola O, Sagrado MG, Conde R, Gonzalez JM. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci. 2008;53:1088-1092. [PMID: 17934820 DOI: 10.1007/s10620-007-9981-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
607 Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 2007;56:792-8. [PMID: 17512312 DOI: 10.1016/j.metabol.2007.01.010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 3.3] [Reference Citation Analysis]
608 Roberts EA. Non-alcoholic steatohepatitis in children. Clin Liver Dis. 2007;11:155-172, x. [PMID: 17544977 DOI: 10.1016/j.cld.2007.02.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
609 Lee K, Haddad A, Osme A, Kim C, Borzou A, Ilchenko S, Allende D, Dasarathy S, McCullough A, Sadygov RG, Kasumov T. Hepatic Mitochondrial Defects in a Nonalcoholic Fatty Liver Disease Mouse Model Are Associated with Increased Degradation of Oxidative Phosphorylation Subunits. Mol Cell Proteomics. 2018;17:2371-2386. [PMID: 30171159 DOI: 10.1074/mcp.ra118.000961] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 6.8] [Reference Citation Analysis]
610 Oh JM, Choi JM, Lee JY, Oh SJ, Kim HC, Kim BH, Ma JY, Kim SK. Effects of palmitic acid on TNF-α-induced cytotoxicity in SK-Hep-1 cells. Toxicology in Vitro 2012;26:783-90. [DOI: 10.1016/j.tiv.2012.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
611 Hoang MH, Kim J, Lee JH, You S, Lee S. Antioxidative, hypolipidemic, and anti-inflammatory activities of sulfated polysaccharides from Monostroma nitidum. Food Sci Biotechnol 2015;24:199-205. [DOI: 10.1007/s10068-015-0027-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
612 Eramo MJ, Lisnyak V, Formosa LE, Ryan MT. The ‘mitochondrial contact site and cristae organising system’ (MICOS) in health and human disease. The Journal of Biochemistry 2020;167:243-55. [DOI: 10.1093/jb/mvz111] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
613 Sharma MR, Polavarapu R, Roseman D, Patel V, Eaton E, Kishor PB, Nanji AA. Transcriptional networks in a rat model for nonalcoholic fatty liver disease: a microarray analysis. Exp Mol Pathol 2006;81:202-10. [PMID: 16949573 DOI: 10.1016/j.yexmp.2006.06.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
614 Yaman H, Cakır E, Ozcan O, Yesilova Z, Ozcan A, Ozgur Akgul E, Kemal Erbil M, Bagci S, Bilgi C, Dagalp K. Elevated urine neopterin levels in nonalcoholic steatohepatitis. Clinical Biochemistry 2005;38:187-90. [DOI: 10.1016/j.clinbiochem.2004.10.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
615 Dohil R, Meyer L, Schmeltzer S, Cabrera BL, Lavine JE, Phillips SA. The Effect of Cysteamine Bitartrate on Adiponectin Multimerization in Non-Alcoholic Fatty Liver Disease and Healthy Subjects. The Journal of Pediatrics 2012;161:639-645.e1. [DOI: 10.1016/j.jpeds.2012.04.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
616 Thyfault JP, Rector RS, Uptergrove GM, Borengasser SJ, Morris EM, Wei Y, Laye MJ, Burant CF, Qi NR, Ridenhour SE, Koch LG, Britton SL, Ibdah JA. Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J Physiol 2009;587:1805-16. [PMID: 19237421 DOI: 10.1113/jphysiol.2009.169060] [Cited by in Crossref: 110] [Cited by in F6Publishing: 112] [Article Influence: 8.5] [Reference Citation Analysis]
617 Sil R, Chakraborti AS. Oxidative Inactivation of Liver Mitochondria in High Fructose Diet-Induced Metabolic Syndrome in Rats: Effect of Glycyrrhizin Treatment: Glycyrrhizin Alleviates Mitochondrial Damage in Metabolic Syndrome. Phytother Res 2016;30:1503-12. [DOI: 10.1002/ptr.5654] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
618 Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P. Activin A in Nonalcoholic Fatty Liver Disease. Activins and Inhibins. Elsevier; 2011. pp. 323-42. [DOI: 10.1016/b978-0-12-385961-7.00015-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
619 Gunji T, Matsuhashi N, Sato H, Iijima K, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Risk factors for serum alanine aminotransferase elevation: A cross-sectional study of healthy adult males in Tokyo, Japan. Dig Liver Dis 2010;42:882-7. [PMID: 20457548 DOI: 10.1016/j.dld.2010.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
620 Garcia-Roves PM. Mitochondrial pathophysiology and type 2 diabetes mellitus. Arch Physiol Biochem 2011;117:177-87. [PMID: 21671709 DOI: 10.3109/13813455.2011.584538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
621 Fotbolcu H, Yakar T, Duman D, Ozden K, Karaahmet T, Tigen K, Kurtoglu U, Dindar I. Aortic elastic properties in nonalcoholic fatty liver disease. Blood Press Monit. 2010;15:139-145. [PMID: 20414104 DOI: 10.1097/mbp.0b013e328339e2c8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
622 Cardoso AR, Cabral-Costa JV, Kowaltowski AJ. Effects of a high fat diet on liver mitochondria: increased ATP-sensitive K+ channel activity and reactive oxygen species generation. J Bioenerg Biomembr. 2010;42:245-253. [PMID: 20373005 DOI: 10.1007/s10863-010-9284-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
623 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
624 Bookman ID, Pham J, Guindi M, Heathcote EJ. Distinguishing nonalcoholic steatohepatitis from fatty liver: serum-free fatty acids, insulin resistance, and serum lipoproteins. Liver Int 2006;26:566-71. [DOI: 10.1111/j.1478-3231.2006.01256.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
625 Sanal MG. The blind men ‘see’ the elephant-the many faces of fatty liver disease. World J Gastroenterol 2008; 14(6): 831-844 [PMID: 18240340 DOI: 10.3748/wjg.14.831] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
626 Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:8713-8742. [PMID: 24837835 DOI: 10.3390/ijms15058713] [Cited by in Crossref: 148] [Cited by in F6Publishing: 141] [Article Influence: 18.5] [Reference Citation Analysis]
627 Nassir F, Arndt JJ, Johnson SA, Ibdah JA. Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice. J Lipid Res 2018;59:967-73. [PMID: 29581157 DOI: 10.1194/jlr.M080952] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
628 Song BJ, Akbar M, Abdelmegeed MA, Byun K, Lee B, Yoon SK, Hardwick JP. Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modifications. Redox Biol. 2014;3:109-123. [PMID: 25465468 DOI: 10.1016/j.redox.2014.10.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
629 Civera M, Urios A, Garcia-torres ML, Ortega J, Martinez-valls J, Cassinello N, del Olmo JA, Ferrandez A, Rodrigo JM, Montoliu C. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab Res Rev 2010;26:187-92. [DOI: 10.1002/dmrr.1070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
630 AlShaalan R, Aljiffry M, Al-Busafi S, Metrakos P, Hassanain M. Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol. 2015;21:64-70. [PMID: 25843191 DOI: 10.4103/1319-3767.153812] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
631 Lydatakis H, Hager IP, Kostadelou E, Mpousmpoulas S, Pappas S, Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int. 2006;26:864-871. [PMID: 16911470 DOI: 10.1111/j.1478-3231.2006.01312.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 4.0] [Reference Citation Analysis]
632 Neumann K, Schiller B, Tiegs G. NLRP3 Inflammasome and IL-33: Novel Players in Sterile Liver Inflammation. Int J Mol Sci 2018;19:E2732. [PMID: 30213101 DOI: 10.3390/ijms19092732] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
633 Kumar S, Verma AK, Rani R, Sharma A, Wang J, Shah SA, Behari J, Salazar Gonzalez R, Kohli R, Gandhi CR. Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis. Hepatology 2020;72:1586-604. [PMID: 32031683 DOI: 10.1002/hep.31167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
634 Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic Fatty Liver Disease Is Associated With Carotid Atherosclerosis: A Case–Control Study. ATVB 2005;25:1045-50. [DOI: 10.1161/01.atv.0000160613.57985.18] [Cited by in Crossref: 249] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
635 Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-? expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007;37:229-35. [DOI: 10.1111/j.1445-5994.2006.01295.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.2] [Reference Citation Analysis]
636 Tsilingiris D, Tzeravini E, Koliaki C, Dalamaga M, Kokkinos A. The Role of Mitochondrial Adaptation and Metabolic Flexibility in the Pathophysiology of Obesity and Insulin Resistance: an Updated Overview. Curr Obes Rep 2021;10:191-213. [PMID: 33840072 DOI: 10.1007/s13679-021-00434-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
637 Rodrigues PM, Afonso MB, Simão AL, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM, Castro RE. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis 2017;8:e2748. [PMID: 28406477 DOI: 10.1038/cddis.2017.172] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
638 Ramasamy I. Update on the molecular biology of dyslipidemias. Clinica Chimica Acta 2016;454:143-85. [DOI: 10.1016/j.cca.2015.10.033] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 12.0] [Reference Citation Analysis]
639 Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, Bo S, Durazzo M, Cassader M. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. The American Journal of Clinical Nutrition 2007;86:661-71. [DOI: 10.1093/ajcn/86.3.661] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
640 Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002;55:689-92. [PMID: 12195000 DOI: 10.1136/jcp.55.9.689] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
641 Kantarceken B, Cetinkaya A, Inanc Tolun F, Yerhan H, Citirik C, Buyukbese MA. Metabolic conditions of fatty liver in non-diabetic obese women. J Endocrinol Invest 2007;30:672-6. [DOI: 10.1007/bf03347448] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
642 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 406] [Article Influence: 30.5] [Reference Citation Analysis]
643 Ibrahim SH, Gores GJ, Hirsova P, Kirby M, Miles L, Jaeschke A, Kohli R. Mixed lineage kinase 3 deficient mice are protected against the high fat high carbohydrate diet-induced steatohepatitis. Liver Int. 2014;34:427-437. [PMID: 24256559 DOI: 10.1111/liv.12353] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
644 Dasarathy S, Kasumov T, Edmison JM, Gruca LL, Bennett C, Duenas C, Marczewski S, McCullough AJ, Hanson RW, Kalhan SC. Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion. Am J Physiol Gastrointest Liver Physiol 2009;297:G567-75. [PMID: 19571235 DOI: 10.1152/ajpgi.00042.2009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
645 Colak Y, Hasan B, Erkalma B, Tandon K, Zervos X, Menzo EL, Erim T. Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target. Clin Res Hepatol Gastroenterol 2021;45:101710. [PMID: 33930586 DOI: 10.1016/j.clinre.2021.101710] [Reference Citation Analysis]
646 Abdalla MY, Mathahs MM, Ahmad IM. Reduced heme oxygenase-1 expression in steatotic livers infected with hepatitis C virus. Eur J Intern Med. 2012;23:649-655. [PMID: 22939811 DOI: 10.1016/j.ejim.2012.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
647 Pirola CJ, Gianotti TF, Burgueño AL, Rey-funes M, Loidl CF, Mallardi P, Martino JS, Castaño GO, Sookoian S. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013;62:1356-63. [DOI: 10.1136/gutjnl-2012-302962] [Cited by in Crossref: 192] [Cited by in F6Publishing: 186] [Article Influence: 19.2] [Reference Citation Analysis]
648 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269. [PMID: 23394092 DOI: 10.2174/1381612811399990344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
649 Romestaing C, Piquet MA, Letexier D, Rey B, Mourier A, Servais S, Belouze M, Rouleau V, Dautresme M, Ollivier I. Mitochondrial adaptations to steatohepatitis induced by a methionine- and choline-deficient diet. Am J Physiol Endocrinol Metab. 2008;294:E110-E119. [PMID: 17986629 DOI: 10.1152/ajpendo.00407.2007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
650 Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-85. [PMID: 20427778 DOI: 10.1056/NEJMoa0907929] [Cited by in Crossref: 1821] [Cited by in F6Publishing: 871] [Article Influence: 151.8] [Reference Citation Analysis]
651 Mager DR, Roberts EA. Nonalcoholic Fatty Liver Disease in Children. Clinics in Liver Disease 2006;10:109-31. [DOI: 10.1016/j.cld.2005.10.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
652 Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007;27:423-433. [PMID: 17403181 DOI: 10.1111/j.1478-3231.2007.01483.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 7.7] [Reference Citation Analysis]
653 Gonzalez-Paredes FJ, Hernández Mesa G, Morales Arraez D, Marcelino Reyes R, Abrante B, Diaz-Flores F, Salido E, Quintero E, Hernández-Guerra M. Contribution of Cyclooxygenase End Products and Oxidative Stress to Intrahepatic Endothelial Dysfunction in Early Non-Alcoholic Fatty Liver Disease. PLoS One 2016;11:e0156650. [PMID: 27227672 DOI: 10.1371/journal.pone.0156650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
654 Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14-22. [PMID: 21115577 DOI: 10.1634/theoncologist.2010-s4-14] [Cited by in Crossref: 293] [Cited by in F6Publishing: 161] [Article Influence: 26.6] [Reference Citation Analysis]
655 Liu Y, Liao L, Chen Y, Han F. Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells. Mol Med Rep 2019;19:4673-84. [PMID: 30957185 DOI: 10.3892/mmr.2019.10139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
656 Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, Itoh Y, Yoshikawa T, Fukui M, Hasegawa G, Nakamura N, Ohta M, Obayashi H, Okanoue T. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011;46:101-7. [DOI: 10.1007/s00535-010-0291-8] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 10.5] [Reference Citation Analysis]
657 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
658 Naguib G, Morris N, Yang S, Fryzek N, Haynes-Williams V, Huang WA, Norman-Wheeler J, Rotman Y. Dietary fatty acid oxidation is decreased in non-alcoholic fatty liver disease: A palmitate breath test study. Liver Int 2020;40:590-7. [PMID: 31762148 DOI: 10.1111/liv.14309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
659 Yoon HJ, Cha BS. Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease. World J Hepatol 2014; 6(11): 800-811 [PMID: 25429318 DOI: 10.4254/wjh.v6.i11.800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
660 Alba LM, Lindor K. Review article: Non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2003;17:977-986. [PMID: 12694079 DOI: 10.1046/j.1365-2036.2003.01493.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 3.8] [Reference Citation Analysis]
661 Sterling RK, Contos MJ, Smith PG, Stravitz RT, Luketic VA, Fuchs M, Shiffman ML, Sanyal AJ. Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008;47:1118-27. [PMID: 18366118 DOI: 10.1002/hep.22134] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
662 Jayakumar S, Guillot S, Argo C, Redick J, Caldwell S. Ultrastructural findings in human nonalcoholic steatohepatitis. Expert Review of Gastroenterology & Hepatology 2014;5:141-5. [DOI: 10.1586/egh.11.9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
663 Puppala J, Siddapuram SP, Akka J, Munshi A. Genetics of nonalcoholic Fatty liver disease: an overview. J Genet Genomics. 2013;40:15-22. [PMID: 23357341 DOI: 10.1016/j.jgg.2012.12.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
664 Wang PW, Kuo HM, Huang HT, Chang AY, Weng SW, Tai MH, Chuang JH, Chen IY, Huang SC, Lin TK, Liou CW. Biphasic response of mitochondrial biogenesis to oxidative stress in visceral fat of diet-induced obesity mice. Antioxid Redox Signal 2014;20:2572-88. [PMID: 24111683 DOI: 10.1089/ars.2013.5334] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
665 Dey P, Mah E, Li J, Jalili T, Symons JD, Bruno RS. Improved hepatic γ-tocopherol status limits oxidative and inflammatory stress-mediated liver injury in db/db mice with nonalcoholic steatohepatitis. Journal of Functional Foods 2018;40:670-8. [DOI: 10.1016/j.jff.2017.12.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
666 Perla FM, Prelati M, Lavorato M, Visicchio D, Anania C. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. Children (Basel) 2017;4:E46. [PMID: 28587303 DOI: 10.3390/children4060046] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
667 Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010;2010:837419. [PMID: 20300479 DOI: 10.1155/2010/837419] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
668 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
669 Pietu F, Guillaud O, Walter T, Vallin M, Hervieu V, Scoazec JY, Dumortier J. Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: long-term results. Clin Res Hepatol Gastroenterol 2012;36:146-55. [PMID: 22154224 DOI: 10.1016/j.clinre.2011.10.011] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
670 García-monzón C, Fernández-bermejo M. A wider view on diagnostic criteria of nonalcoholic steatohepatitis. Gastroenterology 2002;122:840-1. [DOI: 10.1053/gast.2002.00000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
671 Adinolfi LE, Restivo L. Does vitamin E cure nonalcoholic steatohepatitis? Expert Rev Gastroenterol Hepatol. 2011;5:147-150. [PMID: 21476908 DOI: 10.1586/egh.11.27] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
672 Zhan ZY, Wu M, Shang Y, Jiang M, Liu J, Qiao CY, Ye H, Lin YC, Piao MH, Sun RH, Zhang ZH, Jiao JY, Wu YL, Nan JX, Lian LH. Taxifolin ameliorate high-fat-diet feeding plus acute ethanol binge-induced steatohepatitis through inhibiting inflammatory caspase-1-dependent pyroptosis. Food Funct 2021;12:362-72. [PMID: 33325949 DOI: 10.1039/d0fo02653k] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
673 Satoh D, Yagi T, Nagasaka T, Shinoura S, Umeda Y, Yoshida R, Utsumi M, Tanaka T, Sadamori H, Fujiwara T. CD14 upregulation as a distinct feature of non-alcoholic fatty liver disease after pancreatoduodenectomy. World J Hepatol 2013; 5(4): 189-195 [PMID: 23671723 DOI: 10.4254/wjh.v5.i4.189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
674 Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, Sanderson S, Gawrieh S, Krishnan A, Lindor K. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008;47:484-492. [PMID: 18220286 DOI: 10.1002/hep.22063] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
675 Wang J, Brymora J, George J. Roles of adipokines in liver injury and fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:47-57. [PMID: 19072370 DOI: 10.1586/17474124.2.1.47] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
676 Pasarín M, Abraldes JG, Rodríguez-vilarrupla A, La Mura V, García-pagán JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. Journal of Hepatology 2011;55:1095-102. [DOI: 10.1016/j.jhep.2011.01.053] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
677 Blencowe M, Karunanayake T, Wier J, Hsu N, Yang X. Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease. Genes (Basel). 2019;10. [PMID: 31771247 DOI: 10.3390/genes10120966] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
678 Nakano M. Histological study on the resemblance and difference between non-alcoholic steatohepatitis (NASH) and alcoholic liver diseases (ALD). Alcohol Clin Exp Res. 2005;29:230S-235S. [PMID: 16385228 DOI: 10.1097/01.alc.0000191948.27106.85] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
679 Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology 2009;49:1563-70. [PMID: 19399911 DOI: 10.1002/hep.22793] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 7.9] [Reference Citation Analysis]
680 Tenen DG, Chai L, Tan JL. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:1-13. [PMID: 33747521 DOI: 10.1093/gastro/goaa066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
681 Perez M, Gonzáles L, Olarte R, Rodríguez NI, Tabares M, Salazar JP, Jaimes S, García RG, López-Jaramillo P. Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Prev Med. 2011;52:174-177. [PMID: 21147154 DOI: 10.1016/j.ypmed.2010.11.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
682 Kapoor A, Sanyal AJ. Endoplasmic Reticulum Stress and the Unfolded Protein Response.